

**ISSUED TO M/S.** \_\_\_\_\_

**Sl.No**

**NOT TRANSFERABLE**

**Ref.No: BPPI/DRUG/001, Dt. 11.09.2013**

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA  
(Set up under the Department of Pharmaceuticals, Govt of India)  
Redg office: Core No 6, First floor, SCOPE Complex, Lodhi Road, New  
Delhi 110003**

**Working Office: IDPL Corporate office Complex, Old-Delhi-Gurgaon  
Road, Dundahera, Gurgaon 122016 (Haryana)**

**Phone: 0124-4303751, Fax: 0124-2340370 Website: [www.janaushadhi.gov.in](http://www.janaushadhi.gov.in),**

**TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO  
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA  
FOR THE YEAR 2013-2015**

## **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA**

(Set up under the Department of Pharmaceuticals, Govt of India)  
IDPL corporate office Complex, Old-Delhi-Gurgaon Road,  
Dundehera, Gurgaon 122016 (Haryana)

Telephones : 0124-4303751

Fax : 0124-2340370

Email : [procurement.bppi@gmail.com](mailto:procurement.bppi@gmail.com)

### **TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA FOR THE YEAR 2013-2015**

Tender Reference	: <b>BPPI/DRUG/001 dated 11.09.2013</b>
Date of commencement of Sale of tender documents	: <b>12.09.2013</b>
Last date for sale of tender documents	: <b>11.10.2013</b>
Time and date and place pre-bid meeting	: <b>11 AM, 4.10.2013</b> , Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office complex, Old-Delhi Gurgaon Road, Dundahera, Gurgaon. 122016 (Haryana)
Last date and time for receipt of tender documents	: <b>15.10.2013 upto 2 PM</b>
Time and date of opening of tender	: <b>15.10.2013 2.30 PM</b>
Place of opening of tender	: Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office complex, Old-Delhi Gurgaon Road, Dundahera, Gurgaon. 122016 (Haryana)

Address for Communication:

Bureau of Pharma Public Sector  
Undertakings of India, IDPL  
corporate office complex, Old-  
Delhi Gurgaon Road, Dundahera,  
Gurgaon. 122016 (Haryana)

Cost of the Tender Document

**Rs. 2,250/- (Inclusive of Tax)**

Contact Person for clarification if any : 1. Mr. K Chopra, OSD, 0124-4040759, M-9711003043

Email: [ceo.bppi@gmail.com](mailto:ceo.bppi@gmail.com)

2. Mr. P K Santra, GM, 0124-4303751, M-9810448086

Email: [gm.bppi1952@gmail.com](mailto:gm.bppi1952@gmail.com)

*Alternatively, the tender document can be downloaded from the website of BPPI :*

[www.janaushadhi.gov.in](http://www.janaushadhi.gov.in) and [www.pharmaceuticals.gov.in](http://www.pharmaceuticals.gov.in) . However the cost of tender form needs to be paid by way of demand draft drawn in any nationalized bank in favour of “Bureau of Pharma public sector undertakings of India “ payable at Gurgaon along with tender document submission.

---

	<b><u>CONTENTS</u></b>	
<b>S.No.</b>	<b>Descriptions</b>	<b>Page No.</b>
1	Last Date for receipt of Tender	7
2	Eligibility Criteria	7
3	General Conditions	8
4	Technical Bid – Cover “A”	9
5	Price Bid – Cover “B”	13
6	Opening of Cover “A” and Cover “B” of Tender	15
7	Earnest Money Deposit	15
8	Other Conditions	16
9	Acceptance of Tender	18
10	Security Deposit and Agreement	19
11	Methodology for placing orders	20
12	Supply Conditions	22
13	Logograms	25
14	Packing	26
15	Quality Testing	27
16	Payment Provisions	28
17	Handling & Testing Charges	30
18	Liquidated Damages and other penalties	30
19	Deduction and other penalties on account of Quality failure	30
20	Blacklisting in the event of withdrawal from the tender, and Non-Adherence to the Quality Standards and supply schedule	32
21	Saving Clause	36
22	Resolution of Disputes	36
23	Appeal	37
24	Contacting the Purchaser by the Bidder	37
25	Fraudulent and Corrupt Practices	38

Sl.No.	Descriptions	
26	Jurisdiction	40
27	a. Annexure-I (Sales Tax Clearance Certificate)	
28	Annexure-II (Declaration for logogram)	
29	Annexure-III (Declaration for acceptance of tender	
	conditions and compliance of cGMP)	
30	Annexure-IV (Declaration for eligibility in participating	
	the tender)	
31	Annexure-V (Details of EMD submitted)	
32	Annexure-VI (Notarized Under taking )	
33	Annexure-VII (Proforma for Performance Certificate)	
34	Annexure-VIII (Annual Turnover Statement)	
35	Annexure-IX (Details of requirements for Drugs and	
	Medicines)	
36	Annexure-X (Packing Specifications)	
37	Annexure-XI (Agreement format)	
38	Annexure-XII (Performance Security Bank Guarantee)	
39	Annexure-XIII (Details of Manufacturing Unit)	
40	Annexure-XIV (List of Items quoted)	
41	Annexure-XVI (Mandate Form for RTGS)	
42	Annexure-XVII (Check List)	
43	Annexure-XVIII (The Landed Price)	
44	Annexure-XIX (Break up Details of Landed Price)	

## **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA**

### **TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA FOR THE YEAR 2013-2015**

Jan Aushadhi Campaign was started in 2008 with key objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called Jan Aushadhi Stores (JAS). In order to enable a focused and institutional approach to implement the Jan Aushadhi Campaign in particular, BPPI was established in December, 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860 in April, 2010. BPPI follows the provisions of GFR, 2005 as amended from time to time, the CVC guidelines, and instructions from the Department of Pharmaceuticals.

After varied success in last five years and to give a new thrust to Jan Aushadhi Campaign, a New Business Plan has been worked out. It aims to extend the geographical coverage of the scheme, by opening more than 3000 stores during the 12<sup>th</sup> Plan Period. It is proposed to channelize efforts to popularize the scheme in a few selected states and ensure availability of the complete basket of medicines at affordable prices. As proposed in the new business plan, by the end of the current financial year, a minimum of 500 new stores will be opened. The projections for opening of minimum number of stores in the years 2014-15, 2015-16 and 2016-17 are 750, 1000 and 750 respectively.

**Tender Inviting Authority** -Bureau of Pharma Public Sector Undertakings of India, IDPL Complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon 122016 (Haryana) (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

**Tender Accepting Authority** - Bureau of Pharma Public Sector Undertakings of India, (hereinafter referred as **BPPI** unless the context otherwise requires)

**Tender Inviting Authority** invites **Tender for the supply of Drugs and Medicines to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA , for the year 2013-2015.**

## **1.LAST DATE FOR RECEIPT OF TENDERS.**

(a) Sealed Tenders [in two separate covers {Technical bid (Cover “A”) and Price Bid (Cover “B”)}] will be received till **2 PM** on **15.10.2013** by the Tender Inviting Authority, Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon 122016 (Haryana) for the year 2013-2015.

The price bid shall be valid for a period of 120 days from the date of opening of Cover-A (Technical Bid) and prior to the expiry of the bid validity. The Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit. However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

## **2.ELIGIBILITY CRITERIA**

- (a) Tenderer shall be a manufacturer having valid own manufacturing unit duly licensed by licensing authorities or direct importer holding valid import license. Distributors/Suppliers/Agents/Loan licensees are not eligible to participate in the Tenders.
- (b) Average Annual turnover in the last three years i.e. 2010-2011, 2011-2012 and 2012-2013 shall not be less than Rs. 10 Crores and turnover for the year 2012-2013 should also be not less than ***Rs. 10 Crores.***
- (c) Tenderer should at least have 3 years Market Standing as a manufacturer / importer for each drug quoted in the tender as manufacturer / importer.
  - (ii) Tenderer should have obtained permission to manufacture the item/drug quoted (as per specifications laid down in relevant pharmacopoea) in the tender from the competent authority. The imported product will be accepted in Generic / Brand Name with BPPI Logogram affixed / printed.
- (d) Tender should not be submitted for the product(s) for which the firm / company has been blacklisted by any State Government / Central Government / its Drug procurement agencies due to quality failure of the drugs supplied.

- (e) The Company/Firm which has been blacklisted by any State Government/Central Government / its Drug procurement agencies due to quality failure of the drugs supplied should not participate in the tender during the period of blacklisting.
- (f) (i) The Tenderer should give a notarized affidavit that they have not been black listed due to quality failure for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies. (Notarized affidavit as per **Annexure-IV**)
- (ii) During the validity of the tender if the firm / Company is blacklisted by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI by the tenderer firm/ company.

### **3.GENERAL CONDITIONS.**

- (i) A complete set of tender documents may be purchased by any interested eligible person by making an application in writing and upon payment of a non refundable fee as indicated in the advertisement in the form of Demand draft drawn in favor of **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA** payable at Gurgaon.
- (ii) Alternatively, the tender document can be downloaded from the websites [www.janaushadhi.gov.in](http://www.janaushadhi.gov.in) and [www.pharmaceuticals.gov.in](http://www.pharmaceuticals.gov.in) However the cost of tender form needs to be paid by way of demand draft drawn in any nationalized bank in favor of “bureau of Public Pharma sector undertakings of India “ payable at Gurgaon along with the tender.
- (iii) Tender document may be purchased from the office of Tender Inviting Authority between 10.00 A.M. to 5.00 P.M. on or before **11.10.2013** on all working days either in person or by post. Tender Inviting Authority will not be responsible in any way for postal delay.
- (iv) All tenders must be accompanied with Earnest Money Deposit as specified against each drug in **Annexure-IX** of the Tender document .



- (v) Tenders will be opened in the presence of Tenderers/authorized representatives who chooses to attend on the specified date and time.
- (vi) (a) At any time prior to the last date of submission of Tender, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by an amendment. All the prospective Tenderers who have purchased the tender document will be notified of the amendment in writing and that will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of tenders.
- (b) Any person who has downloaded the tender document should watch for amendment, if any, on the website [www.janaushadhi.gov.in](http://www.janaushadhi.gov.in) and [www.pharmaceuticals.gov.in](http://www.pharmaceuticals.gov.in) for which BPPI will not issue any separate communication to them.
- (vii) Interested eligible Tenderers may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10.00 AM and 5.00 PM. Pre-bid meeting will be held at BPPI, IDPL corporate office complex, Dundahera at 11 AM on Oct 4, 2013.
- (viii) Certain products would be reserved for Central Public Sector Undertakings (CPSU's). Orders for these items will be first placed with CPSU's.

#### **4. TECHNICAL BID - COVER "A"**

- 4.1. The Tenderer should furnish the following documents in a separate cover hereafter called "**Cover A**". (All the documents submitted should be signed and sealed by the Tenderer in each page and Xerox copies of the documents should be attested by the Tenderer and also be notarized in each page)
- (a) Earnest Money Deposit, shall be as indicated against each drug in Annexure-IX of the tender document in the form of **Bankers Cheque or Demand Draft** favoring "Bureau of Pharma Public Sector Undertakings of India " , payable at Gurgaon and the Tenderer should also enclose split up details of EMD for each item along with **Bankers Cheque or Demand Draft**. EMD in any other form like *cheque/cash/postal order* etc. will not be accepted.

- (b) Documentary evidence for the constitution of the Company/Firm such as Memorandum and Articles of Association, Partnership deed, Permanent Registration Number etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor. The list of present Directors in the Board of the Company duly certified by a Company Secretary of the Company/Practicing Company Secretary / Chartered Accountant to be furnished.
- (c) The Tenderer should furnish notarized photocopy of Manufacturing Licence for the product, duly approved by the Licensing Authority for each and every product quoted as per specification in the tender. The licence must have been duly renewed up to date and the items quoted shall be clearly highlighted in the licence. Original documents should be produced for verification when demanded. However, if renewal application for Manufacturing licence has been filed, copy of same duly receipted by drug authorities must be enclosed.
- (d) Notarised photocopy of import license (in Form 10 with Form 41), as per Rule 122A of the Drugs and Cosmetics Act 1940, if the product is imported should be furnished. The licence must have been renewed up to date. A copy of a valid licence for the sale of Drugs imported by the firms issued by the State Licensing Authority shall be enclosed. Original documents should be produced for verification when demanded.
- (e) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Tenderer should be enclosed with the tender duly signed by the Authorized signatory of the Company/Firm and such authorized officer of the Tenderer should sign the tender documents.
- (f) Authorization letter nominating an officer of the Tenderer to transact the business with the BPPI.
- (g) Market Standing Certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items). In case of direct importer, evidence for importing the said items for the last 3 years such as bill of lading, bill of entry for last three years and certificate of analysis are to be produced.

- (h) Performance statement of manufacture/import to establish 3 years market standing as per format in **Annexure-VII**.
- (i) Non-conviction Certificate issued by the Drugs Controller of the State certifying that the firm/company has not been convicted.
- (j) Current Good manufacturing practices Certificate (cGMP) as per revised Schedule- 'M' (for manufacturers only) issued by the Licensing Authority. The Tenderer shall also furnish a notarized declaration in the format given in **Annexure-III** declaring that the Tenderer complies with the requirements of cGMP (**as per revised Schedule-'M'**). In case of Imported drugs, labels and product literature of all quoted product(s) must be submitted with WHO-GMP/certificate which is at par with WHO-GMP issued by exporting countries like U.S. FDA etc/COPP certificate of their Principal Manufacturing company/firm.
- (k) Annual turnover statement for 3 years i.e., 2010-2011, 2011-2012 and 2012-2013 should be furnished in the format given in **Annexure-VIII** duly certified by the chartered Accountant.
- (l) Copies of the Annual reports including the Balance Sheet and Profit and Loss Account for the last three years i.e. 2010-2011, 2011-2012 and 2012-2013 duly certified by the Chartered Accountant.
- (m)
  - a. Sales Tax Clearance certificate, as on 31.03.2013 (as per form attached in **Annexure-I**).
  - b. Latest Income tax assessment orders/returns filed are to be attached .
- (n)
  - (i) Undertaking (as in the proforma given in **Annexure-II**) for embossment of logo on strip of tablets, capsules, on labels of vials, Ampoules, bottles, tubes etc. as the case may be, and for supply of tablets/capsules in strips as per conditions specified under Clause 13 herein, notarized by the Notary Public.
  - (ii) Undertaking (as in the proforma given in **Annexure-II (A)**) for affixing the Jan Aushadhi logo on the Secondary/Primary packing for the imported items along with Brand/Trade names.
- (o) The details containing the name and address of the manufacturing premises / importing unit where the items quoted are actually manufactured should be given as per the format in **Annexure-XIII** along with exact address of registered/Corporate office.

- (p) Documents, if any, to show that the manufacturing unit/importer has been recognized by any other Indian / International Standard Organizations as applicable etc.
- (q) Details of technical personnel employed in the manufacturing and testing of drugs (Employee Name, Qualification, and Experience) as endorsed in license.
- (r) List of items quoted (The name & Drug code of the Items quoted, annual production capacity of individual drug earmarked for BPPI and amount of EMD for each drug alone should be Furnished and **the rate of those items should not be indicated in this list**), as shown in the **Annexure-XIV** should be given in duplicate.
- (s) A Checklist (Annexure- XVII) indicating the documents submitted with the tender document and their respective page number shall be enclosed with the tender document. The documents should be serially arranged as per this **Annexure-XVII** and should be securely tied or bound. If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will be submitted as a separate set with the same tender. But a bidder will be allowed to submit only one offer for one product.
- (t) The tender document should be signed by the authorized official of the Tenderer in all pages with office seal.
- (u) All the documents enclosed with the tender document should also be signed by the authorized official of the Tenderer.

4.2. The above documents should be sealed in a separate Cover Superscribed as "**TECHNICAL BID - COVER "A" - TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA FOR THE YEAR 2013-2015 DUE ON 15.10.2013 AT 2 PM. AND ADDRESSED TO THE TENDER INVITING AUTHORITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA , IDPL COMPLEX, DUNDAHERA, GURGAON 122016**"

## **5. PRICE BID - COVER "B"**

5.1. Cover "B" contains the Price Bid of the Tenderer.

- (i) Bid should be typewritten and every correction and interlineations in the bid should be attested with full signature by the Tenderer, failing which the bid will be treated as ineligible. Corrections done with correction fluid should also be duly attested.
- (ii) Each page of the price bid should be duly signed by the Tenderer affixing the office seal.
- (iii) (a) The Tenderer shall fill in the rate in the **Annexure-XVIII** and **Annexure-XIX** for the items quoted and also in the Compact Disc (CD) (supplied with tender document) and such filled in **Annexure-XVIII** and **Annexure-XIX** along with the Compact Disc (CD) (Soft Copy) should be submitted.  
  
(b) The Tenderers who have downloaded Tender document, shall also download and copy the **JAD2013.XLS** (Excel) file in the Compact Disc (CD). Such Compact Disc (CD) may be used for quoting the rate in soft copy.
- (iv) In determining the lowest evaluated price, (the rate quoted per unit or landed price in **Annexure-XVIII**) the evaluation shall include all taxes and duties such as customs duty, excise duty, sales tax etc. subjected to the following:
- (v) The rate quoted in column 8 of **Annexure-XVIII** should be for a unit and for the given specification. The Tenderer is not permitted to change/alter specification or unit size given in the **Annexure XVIII**.
- (vi) The Tenderer is required to furnish the break up details of landed price in **Annexure-XIX**.
- (vii) The rate quoted in column 8 of **Annexure-XVIII** and in column 8 of **Annexure-XIX** should be one and the same.

- (viii) The details of products rates and manufacturing capacity (for each item individually) given in **Annexure-XVIII** should be entered clearly given along with the tender.
- (ix) The bidder shall necessarily quote the excise duty or customs duty applicable and when the item is excisable or imported as the case may be. The relevant chapters and tariff applicable should be indicated for each item.
- (x) The bidder shall specifically mention “ **EXEMPTED** ” when the item is excisable but exempted for the time being, based on turn over or for any other grounds by the notification issued by the Government of India (**Also refer clause 16.6**).
- (xi) The bidder once quoted the excise rate is not permitted to change the rate/amount unless such change is supported by the notification issued by the Government of India or by the order of the court, after submission of Tender.
- (xii) The bidder, who has quoted excise duty as “**NIL**” in **ANNEXURE-XIX** and the item is excisable, at award of contract, will be eligible for payment of excise duty only on production of invoices drawn as per Central Excise Rules.

5.2. The Tenderers shall submit duly signed **Annexure-XVIII** and **Annexure- XIX** in a sealed cover Superscribed as “**PRICE BID COVER “B”**” -

**TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS FOR THE YEAR 2013-2015”.**

The "Cover-B" should also be addressed to the **TENDER INVITING AUTHORITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS, GURGAON, HARYANA 122016.**

5.3. Two separate sealed covers {Technical bid (Cover “A”) {Refer Clause No.4.2} and Price Bid (Cover “B”)} { Refer clause 5.(2) } shall be placed in a cover which shall be sealed and Superscribed as

**“TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS FOR THE YEAR 2013-2015 DUE ON 15.10.2013 AT 2 PM”** and addressed to the

**TENDER INVITING AUTHORITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS, GURGAON, HARYANA 122016**, which shall be submitted within the date and time as specified in Clause 1(a).

- 5.4. If the last date for submission of Tender is declared holiday, the tenders may be submitted on the next working day upto 10.30 A.M.

## **6. OPENING OF COVER "A" AND COVER "B" OF TENDER**

6.1 Only authorized official as indicated in Clause 4.1. (f) are entitled to be present at the time of opening of Technical Bid - Cover "A" of the tender submitted by them.

- 6.2 Tenderers, who are found eligible on satisfying the criteria for technical evaluation and inspection, will only be invited to be present at the time of opening of Price Bid - Cover "B" of the tender.

## **7. EARNEST MONEY DEPOSIT**

- 7.1.(a) The Earnest Money Deposit referred to under Clause 4.1(a), shall be for the amount as indicated against each drug in Annexure-IX of the tender documents. In case a Tenderer is quoting for more than one drug, the Earnest Money Deposit payable by such Tenderer shall be the aggregate total of the Earnest Money Deposit for all the drugs quoted by such bidder. The bidders are required to furnish the breakup of the Earnest Money Deposit for the items quoted along with the **Bankers Cheque or Demand Draft** in the format as per Annexure-V. **The Earnest Money Deposit shall be paid in the form of Bankers Cheque or Demand Draft in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS , Gurgaon.**

- 7.3. (i) The tender submitted without sufficient EMD will be summarily rejected.
- (ii) The Earnest Money Deposit will be refunded to the successful bidders within 60 days from the date of signing the contract agreement and on the deposit of Security Deposit.
- (iii) The Earnest Money Deposit (EMD) of the unsuccessful bidders will be returned within 60 days after finalization of tender.

- (iv) The Earnest Money Deposit (EMD) will be forfeited, if the Tenderer withdraws his bid / non execution of agreement / undertaking within the period prescribed.
- (v) The Earnest Money Deposit (EMD) will be forfeited, in case of the lowest bidder, fails to execute the contract agreement and / or deposit the security Deposit within the stipulated time.
- (vi) The Tenderer, whose manufacturing unit is found to be not complying with the cGMP (but furnished an affidavit in **Annexure-III**) during inspection, will be levied with a fine of Rs.50,000/- or the expenditure incurred by the BPPI in such inspection, whichever is higher. This fine amount shall be deducted from the EMD deposited by the bidder or any other amount payable to them. The amount will be deducted without any notice. In case of deficit, legal action will be launched against the bidder for recovery.

## **8.OTHER CONDITIONS**

- 8.1.(i) The details of the required drugs, medicines, etc., are shown in **Annexure-IX**. *The tender quantity mentioned here in is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased* by the BPPI, at its discretion, depending on its actual need. Though the tentative quantity is indicated in the agreement, the BPPI, will confirm the actual requirement then / there through purchase order/orders. The tenderers shall supply the drugs only on the basis of the purchase order issued by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.
- (ii) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the agreement / undertaking.
  - (iii) The rates quoted shall not be varied with the order quantity or the destination during the full contract period.
- 8.2. Tender has been called for in the **generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition and strength of each product should be as per specifications given in **Annexure-IX**. Any variation, if found, will



result in rejection of the tender. However the imported/combination drugs are allowed to quote in trade / brand name.

- 8.3. Rates (inclusive of Excise Duty, Customs duty, transportation, insurance, and any incidental charges, but exclusive of VAT (Sales Tax)) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.
- 8.4. Each bid must contain not only the unit rate but also the total value of each item quoted for supply in the respective columns. The aggregate value of all the items quoted in the tender shall also be furnished.
- 8.5. The price quoted by the tenderers shall not, in any case exceed the controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer. Tender Inviting Authority at its discretion, may exercise, the right to revise the price at any stage so as to conform to the controlled price or MRP or the selling price of the tenderer as the case may be. This discretion will be exercised without prejudice to any other action that may be taken against the Tenderer.
- 8.6. The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly this clause will be applicable for all orders placed during the contract period.
- 8.7. No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

- 8.8. For the drug formulation like Injections, Liquid orals, Tablets and Capsules, rates should be quoted only for the composition stated in the tender. Blood products should be supplied only after getting HIV and Hepatitis-B screening certificate. A copy of these Certificates duly notarized should be sent with every consignment and every invoice.
- 8.9. Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.
- 8.10. The Tenderer shall allow inspection of the factory at any time by a team of Experts/Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/Firm does not allow for any such inspection, their tenders will be rejected during the currency of the contract.

#### **9.ACCEPTANCE OF TENDER**

- 9.1. Evaluation of the tender will be done on the basis of rate per pack inclusive of various taxes and charges (landed price) as mentioned in **Annexure-XVIII** and **Annexure-XIX** shall be worked out for determining the L1 rate (Lowest rate). As per CVC guidelines, negotiations will be done with L1 bidder only.
- 9.2. BPPI , reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.
- 9.3. BPPI or its authorized representative(s) has the right to inspect the factories of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections.
- 9.4. The acceptance of the tenders will be communicated to the lowest Tenderers in writing.

## **10.SECURITY DEPOSIT AND AGREEMENT**

### **10.1Security Deposit:**

On being informed about the acceptance of the tender and at the time of signing the Agreement, the lowest Tenderer shall pay the Security Deposit @ 5% of the value of order in the form of ***Demand Draft or irrevocable Bank Guarantee*** in favour of Bureau of Public Sector Undertakings of India from any nationalized bank. In case the Security Deposit is paid in form of Bank Guarantee, the bank guarantee shall be valid for a period of 2 years from the date of communication of the acceptance letter from the Tender inviting Authority. The format of Bank Guarantee is at **Annexure-XII**.

- 10.2. The lowest Tenderer shall execute an agreement on a non- judicial stamp paper of value of Rs.100/- (stamp duty to be paid by the Tenderer) within 15 days from the date of the intimation from BPPI informing that his tender has been accepted. The Specimen form of agreement is available in **Annexure-XI**.
- 10.3. The Tenderer shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons what so ever.
- 10.4. All notices or communications relating to and arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if delivered to him or left at the premises, places of business or abode as provided by the tenderer.
- 10.5. If the lowest Tenderer fails to execute the agreement and/or to deposit the required security deposit within the time specified or withdraws the tender, after the intimation of the acceptance of the tender or owing to any other reasons to undertake the contract, the contract will be cancelled and the Earnest Money Deposit deposited by the tenderer along with the tender shall stand forfeited by the BPPI and the firm will also be liable for all damages sustained by the BPPI apart from blacklisting and other penal actions.
- 10.6. The security deposit of supplier will be returned by BPPI only after the supplier has given undertaking to replace such medicines and indemnify BPPI against any losses on account of quality parameters.

## **11.METHODOLOGY FOR PLACING ORDERS**

For the above purpose the following procedures will be adopted

- (a) After the conclusion of Price Bid opening (Cover B), the lowest offer of the Tenderer is considered for negotiation and rate arrived after negotiation is declared as the lowest rate and that tenderer as lowest evaluated for the item (s) for which the tender has been invited.
- (b) The Tenderer, who has been declared as lowest tenderer for certain item(s), shall execute necessary agreement for the supply of the tendered quantity of such drugs/medicines as specified in the Tender Document on depositing the required amount as Performance Security and on execution of the agreement such Tenderer is eligible for the placement of Purchase Orders.
- (c) If two or more than two Tenderers are declared as lowest suppliers for the same item(s), such Tenderers shall execute necessary agreement as specified in the Tender Document on depositing the required amount as Performance Security and on execution of the agreement such Tenderer is eligible for the placement of Purchase Orders for such item(s) for which they are declared as lowest. Placement of order shall be shared equally amongst these bidders.
- (d) In the case of purchase of goods where the quantity offered at the lowest price is less than the total quantity required, the BPPI may, after placing orders with the lowest evaluated Tenderer for the entire quantity offered by such Tenderer subject to his ability to supply, require all the other eligible Tenderers who participated in the tender and offered a price higher than that offered by the lowest evaluated Tenderer, to submit sealed offers of the quantity they would be willing to supply at the price quoted by the lowest evaluated Tenderer, and thereafter place orders for the remaining required quantity with all those who match the lowest evaluated price such that those who bid lower prices in the original tender get a higher priority for supply.
- (e) If the lowest supplier has failed to supply the required Drugs/Medicines within the stipulated time or within the extended time, as the case may be, BPPI will cancel such purchase orders and on cancellation, BPPI will place Purchase Orders with L2 (L3 if L2 also fails) or to the other tenderers at the risk and cost of the defaulted supplier, subject to the maximum production capacity, such Tenderer or other tenderers shall execute necessary agreement indicating the production capacity as specified in the Tender Document and deposit the required amount as Performance Security as the prior conditions to become eligible for placement of Purchase Orders for the item(s) quoted by them.

- (f) If the supplier fails to supply the Drugs /Medicines for any of the three Purchase Orders placed, at any point of time, either fully or partly, within the stipulated time, BPPI is at liberty to place Purchase Orders with other Tenderers ( in ascending order, viz., L2,L3 and so on) at the price offered by them and in such cases the supplier is liable to indemnify BPPI, WITH OUT ANY PROTEST OR DEMUR, for the difference in cost incurred by BPPI and the BPPI is entitled to recover the difference in cost from the amount due/payable to the supplier.
- (g) Notwithstanding anything contained in para (f) above, the supplier, after committing the default in supply either partly or fully, can inform the BPPI about his willingness to execute the Purchase Order during the tender period. The BPPI at discretion, may consider the willingness of the supplier on merit. However, such supplies will be subjected to the levy of Liquidated Damages, unexecuted fine and other penalties as stipulated in the tender document, agreement and purchase order.
- (h) The supplier shall start supply of the Drugs/Medicines required by BPPI at the destination mentioned in the schedule, within the period stipulated here under and in the Purchase Order.
- (i) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.
- (j) The supplier shall supply the Drugs/Medicines at the specified destination and submit a copy of the excise invoice, Purchase order, Delivery Challan and other relevant documents at the destinations.
- (k) After supply of Drugs/Medicines at the specified destinations, the supplier shall submit Excise Invoice (Original), Test Report (Batch Wise) and other relevant documents etc., at the Head Office, BPPI for claiming payment.
- (l) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also the supplier shall ensure the quantity relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice. Any variation will be viewed seriously and the payment for the supply will be released only after confirmation of the batch number by the supplier. At the discretion of the BPPI the variations in batch numbers in

Invoices Vs. actual supply will be accepted. However, any abnormal variation may lead to rejection of consignment/goods and Blacklisting of the product/supplier at the discretion of BPPI.

- (m) It is the duty of the supplier to supply Drugs/Medicines at the destinations mentioned in the Purchase Order and supply shall conform to the conditions mentioned in the provisions of tender documents, viz., logo, nomenclature, specification etc.,
- (n) Subject to para (q) above, BPPI will process the invoices submitted by the supplier and the payments against supply will be made, within 30 days from the date the Drugs/Medicines supplied has been declared of STANDARD QUALITY, by the Empanelled laboratory of BPPI subject to various terms and conditions of the tender provided the invoices and the batch numbers declared by the tenderer at the Head office and Warehouses of BPPI are the same.
- (o) Subject to the conditions mentioned in the Purchase Order, Tender Document, Agreement executed by the supplier and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 30 days from the date of receipt of payment, failing which BPPI will not entertain any claim thereafter.
- (p) BPPI reserves the right to place upto 50% additional purchase order of the quantities as contracted.

## **12. SUPPLY CONDITIONS**

- 12.1. Purchase orders along with the place of supply (destinations) will be issued to the Tenderer(s) at the discretion of the BPPI
- 12.2. Within 3 days from the receipt of purchase orders the Tenderer should upload on the website of the BPPI and inform through fax the confirmation for the receipt of the purchase order.

- 12.3. The Tenderer should also upload the details of supply dates as specified in Annexure, on the BPPI website within 7 days from the receipt of the purchase order. The same should also be Faxed and mailed to BPPI simultaneously.
- 12.4.(a) The supplier shall supply at least **50%** of the ordered quantity within 30 days from the date of purchase order and the balance quantity within 45 days from the date of purchase order at the destinations mentioned in the purchase order. If the above day happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day. In case of Non- execution of the order either partially or fully, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information. If the Tenderer fails to execute the supply within the stipulated time (30/45 days), the BPPI is at liberty to make alternative arrangement for purchase of the items of drugs and medicines for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 19.
- (b) The supplier may continue the supply of unexecuted quantity after 45<sup>th</sup> day, however Liquidated Damages as specified in clause 18.1 and 18.2 of the tender conditions, will be levied on the quantity supplied after the 45<sup>th</sup> day. However no supplies will be normally accepted after 5 PM of 75<sup>th</sup> day from the date of issue of the purchase order.
- 12.5. The supplier is entitled to receive a incentive payment@ **0.25%** flat on the order value PROVIDED the entire order is completed within 20 days.
- 12.6. The total quantity for the approved items of the respective L1 bidder shall not exceed the capacity earmarked for BPPI by the bidder. In the event of the bidder becoming L1 for more than one item, if the total annual quantity for such items is more than the capacity earmarked for BPPI, BPPI reserve the rights to place order for any item(s) within his production capacity.
- 12.7. Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders.
- 12.8. All supplies will be scheduled for the period from the date of acceptance till the completion of the tender in installments, as may be stipulated in the Purchase Order,

subject to various conditions mentioned here under. The supplied medicines and Drugs (covered in SCHEDULE “P” of Drugs and Cosmetics Act) should have the prescribed potency throughout the shelf life period as prescribed in the Drugs and Cosmetics Act 1940 and rules there under and in relevant Pharmacopoeias.

- 12.9. The Tenderer must submit an Analysis report from a Government approved Laboratory for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned back to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs and medicines supplied by the successful Tenderer shall be of the best quality and shall comply with the specifications, stipulations and conditions specified in the tender.
- 12.10. Tenderer should supply the product, within 45 days from the date of manufacture of that product. In case, the product is received after 45 days from date of manufacture and the product is not consumed before its expiry date, the supplier should replace the short expiry/expired quantity with fresh stock of longer shelf life, otherwise the expired product will be returned to the supplier and the value equal to the cost of expired quantity will be recovered from any dues payable. The date manufacture should always be later than date of purchase order.
- 12.11. The order stands cancelled at the end of 75th day from the issue of the purchase order after levying penalty on the value of unexecuted order as specified under Clause 18.3. Further, the Tenderer shall also be liable to pay other penalties as specified under Clauses 19. Security Deposit of such suppliers shall also be forfeited. However if such default occurs for 3 or more purchase orders penal action like blacklisting from participating in present and future tenders of BPPI shall be enforced by the BPPI
- 12.12. The Tenderer shall take back drugs, which were supplied within 45 days from the date of purchase order which are not utilized by the BPPI within the shelf life period based on mutual agreement.
- 12.13. If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The exceptional



events does not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

- 12.14. The supplier shall not be liable to pay LD and forfeiture of security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

### **13.LOGOGRAMS**

Logogram means, wherever the context occurs, the design as specified in

**Annexure-II. The name of the drug shall be mentioned in Hindi and English .**

- 13.1. Tenders for the supply for Drugs and medicines etc., shall be considered only if the Tenderer gives an undertaking that the product(s) will be prepared as per the specifications such as strength, minimum size and packed with appropriate size of the strips/blisters and with the logogram of proportionate size either printed or embossed on tablets and capsules, bottles etc., as per the design enclosed as per **Annexures-II.II-A.**
- 13.2. All tablets and capsules have to be supplied in standard packing of 10 x 10 in strip or blister packing with printed logogram of proportionate size and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules wherever it applies. Affixing of stickers and rubber stamps shall not be accepted.
- 13.3. Vials, Ampoules and Bottles containing the items tendered for should also carry the printed logogram of proportionate size.
- 13.4. Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of agreement / violation of tender conditions and action will be taken to blacklist the product and/or fine will be deducted from the amount payable as per condition in Clause 18.5. However if such failure continuous despite notice, will be viewed as a serious lapse.

Tenderers who are not willing to agree to conditions above will be summarily rejected.

#### **14.PACKING**

14.1. The drugs and medicines shall be supplied in the package specified in **Annexure-IX** and **Annexure-X** and the package shall carry the logograms of proportionate size specified in **Annexures-II, II -A**. Affixing of labels in Smaller size will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 18.5

- 14.2. The minimum size of each tablet should be 6.4 mm in diameter. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5.
- 14.3. The packing in each carton shall be strictly as per the specification mentioned in **Annexure-X**. The outer carton should be of white board with a minimum of 300 GSM with laminated packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 450 GSM. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label.
- 14.4. The caps of bottle preparations should not carry the name of the supplier.
- 14.5. The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intra Muscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.
- 14.6. It should be ensured that only first hand fresh packaging material of uniform size, including bottle and vial, is used for packing.
- 14.7. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

- 14.8. Packing should be able to prevent damage or deterioration during transit.
- 14.9 In the event of items of drugs supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 18.5.

## **15.QUALITY TESTING**

- 15.1. Samples of supplies in each batch will be chosen at the point of supply or distribution/storage points for testing. The samples will be sent to different laboratories including Government Drugs Testing Laborator for testing as decided by the BPPI Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 17.
- 15.2. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found “Not of Standard Quality”, the cost of entire batch paid will be recovered whether consumed fully/partially. Also action will be initiated for blacklisting as per clause No.19 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
- 15.3. In the event of the samples of Drugs and medicines supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 19.
- 15.4. The supplier shall furnish to the BPPI the Evidence of bio- availability and/or bio-equivalence reports for certain critical drugs upon demand.

- 15.5. The supplier shall furnish evidence of the basis for expiration dating and other stability data concerning the commercial final package on request by the BPPI In case of any adverse report in the field, the B.M.R/B.P.R for the particular batch of the product(s) supplied shall be produced when demanded.
- 15.6. The products should conform to the standards of IP/BP/USP/EP/JP as the case may be. In case the product is not included in the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs, respective Country's Pharmacopial standards shall be acceptable (even if the product is official in IP).
- 15.7 The case of admixture of drugs / mixing of various batches in the Primary / Secondary and/or Tertiary packing, such case will be treated as a violation of tender conditions and fine will be levied as per clause 19. If such lapses happens more than twice in a tender period such cases will be treated as "Misbranded Drugs".

#### **16.PAYMENT PROVISIONS**

- 16.1. No advance payments towards costs of drugs, medicines etc., will be made to the Tenderer.
- 16.2. Payments towards the supply of drugs and medicines will be made strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original (**Annexure-XVI**) to make the payment through RTGS/Core Banking/NEFT and the change of Bank Account during the validity of the tender will not be entertained normally.
- 16.3. All bills/Invoices should be raised in triplicate and in the case of excisable Drugs and Medicines, the bills should be drawn as per Central Excise Rules in the name of Bureau of Pharma Public Sector Undertakings of India. IDPL Complex, Dundehera, Gurgaon 122016 or in the name of any other authority as may be designated.
- 16.4. (i) Payments for supply will be considered only after supply of minimum 80% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI

- (ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 80% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:
  - (a) If the Tenderer have supplied at least 80% of the quantity ordered in the subsequent purchase order within 60 days from the issue of such purchase order.
  - (b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid after 60 days from the date of last supply.
  - (c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.
- 16.5. If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.
- 16.6.(a) In case of any increase or decrease in the taxes, such as excise duty, customs duty, sales tax, VAT etc., after the date of submission of tenders and during the tender period, such variation in the taxes will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned Excise authorities and also must claim the same in the invoice separately. However the basic price structure and the price of the Drugs approved under the tender shall not be altered.  
Similarly if there is any reduction in the taxes and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender.

Any increase or decrease in taxes and statutory levies will be considered based on the notification issued by the Government.

(b) In case of successful bidder enjoying excise duty exemption on any criteria of turnover, area based etc., such bidder will not be allowed to claim excise duty at a later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.

#### **17. HANDLING & TESTING CHARGES:**

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

#### **18. LIQUIDATED DAMAGES AND OTHER PENALTIES:**

- 18.1. If the supply reaches the designated places or Central Warehouse between 5 PM of the 45<sup>th</sup> day and 5 PM of 75<sup>th</sup> day from the date of issue of the purchase order, a liquidated damages will be levied at 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply. If the 45<sup>th</sup> day happens to be a holiday the supply will be accepted on the next working day without any penalty.
- 18.2. If the supply is received in damaged condition it shall not be accepted.
- 18.3. All the Tenderers are required to supply the product(s) with printed logogram of appropriate size on the strips, blisters, vials, ampoules & bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product and/or a separate damages will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.14.11 and 13.4.

#### **19. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:**

- 19.1. If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the receipt of the letter from the BPPI. Such stock shall be taken back at the expense of the Tenderer. The BPPI has the right to destroy such "NOT OF STANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above.

without further notice, and shall also collect demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated.

- 19.2. If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odor, unsound, inferior in quality or description or otherwise faulty or unfit for consumption, then the contract price or prices of such articles or things will be recovered from the Tenderer, if payment had already been made to him. In other words the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of "NOT OF STANDARD QUALITY" whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.
- 19.3. For the supply of Adulterated/Spurious/Misbranded drugs to BPPI, the firm/company shall be blacklisted by BPPI and no further supplies shall be accepted from the firm/company. The Tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs and Medicines for a period of 5 years from the date of blacklisting. In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs and Medicines for a period of 2 years from the date of blacklisting. In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Security deposit will also be forfeited without any intimation.
- 19.4. The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders, if the source of supply is not furnished.
- 19.5. The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- 19.6. The BPPI will be at liberty to terminate, without assigning any reasons thereof, the contract either wholly or in part on 30 days notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Security deposit.
- 19.7. For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered personally from the Tenderer or from his properties, as per rules besides forfeiture of Security deposit.
- 19.8. Non performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years besides forfeiture of Security deposit.
- 19.9. In the event of making Alternative Purchase, as specified in Clause 12.4 (a), Clause 14.11 and in Clause 15.3 penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.
- 19.10. In all the above conditions, the decision of the BPPI shall be final and binding.

## **20. BLACK LISTING IN THE EVENT OF WITHDRAWAL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE**

### **20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER**



- (a) If the Tenderer(s) fails to execute the agreement / to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be blacklisted for a period of 2 years by BPPI from the date of intimation besides forfeiture of Security deposit.
- (b) The Tenderers who have withdrawn after participating in the tender will be blacklisted for a period of 2 years from the date of intimation by BPPI apart from forfeiture of the Security Deposit/EMD.

### **BLACKLISTING FOR QUALITY FAILURE**

#### **20.2.1. Quality Test by the Empanelled Laboratories of BPPI**

- a. Each and every batch of drugs/medicines supplied by the supplier shall be subjected to quality test by the Empanelled laboratories.
- b. The samples are collected from the Warehouses from each batch of supply of the same drugs and after eliminating the common batch, samples shall be taken in random, decoded and will be sent to the empanelled testing laboratories for testing the quality of drugs.
- c. If such sample passes quality test in all respects, BPPI will instruct its Warehouses to release such items of drugs .
- d. Such quality passed batches if received after declaration of result of the earlier supply, the same will be again subjected to testing and the latest report of that particular batch will be binding on the entire quantity of the batch supplied and recovery will be made for the entire quantity of that batch irrespective of purchase order date or date of supply etc.
- e. If the sample fails in quality test and report is received certifying that sample is “NOT OF STANDARD QUALITY”, one more sample shall be drawn from the same batch and to be sent to Government Laboratory for quality testing.
- (i) If such sample passes the quality test as per the report of Government Laboratory, the drugs representing the sample shall be qualified for issue to various Institutions.

- (ii) If such sample fails in the quality test, as per the report of the Government Laboratory, the drugs of the batch are not qualified for issue and the supplier shall take back the drugs supplied in that batch, besides taking other actions as per the Tender conditions by BPPI.
- (iii) If such Sample fails in quality test for ASSAY content of less than 50% as per the Government Analyst report, such product of the tenderer will be blacklisted for two years.
- (iv) If 4 batches of a particular item supplied by the supplier is reported to be failing in ASSAY content (above 50% but below prescribed limit) and/or other parameters, then the particular item of the firm shall be blacklisted after observing procedure laid down in Para 20.2.4 besides forfeiture of Security Deposit of that particular product(s).
- f. In all the cases the reports received from the Government Drug Testing Laboratory will be conclusive and final and binding on the suppliers.

#### **20.2.2 Quality Test by Statutory Authorities:**

- (a) On complaint from Drug Inspector(s) during their Test of field sample, that the particular drug has been reported to be of "NOT OF STANDARD QUALITY", the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals will be retrieved. If the sample is reported to have less than 50% of content, the particular product will be **blacklisted for 2 years from the date of intimation of blacklisting.**
- (b) If 4 batches of a particular item supplied by the supplier is reported to be failing in **ASSAY content (above 50% but below prescribed limit) and/or other parameters**, then the particular item of the firm shall be blacklisted for a period of **2 years** from the date of intimation after observing procedure laid down in Para 20.2.4.
- (c) If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded by the Government Authorities during the relevant tender period, the company/firm shall be blacklisted for a period of **5 years from the date of blacklisting** after observing procedure laid down in Para 20.2.4.

### **20.2.3 BLACKLISTING OF THE SUPPLIER FOR QUALITY FAILURE:**

- a. In case of any sample even in one batch, declared as Adulterated/spurious/ Misbranded by the Government Authorities during, the company/firm shall be blacklisted for a period of **5 years** from the date of intimation besides forfeiture of security deposit in full after observing the procedure laid down in Para 20.2.4.
- b. If the supplier supplied more than one item and 50% of such items are blacklisted, the firm is liable to be blacklisted for a period of 2 years from the date of intimation after observing the procedure laid down in Para 20.2.4.

### **20.2.4 Procedure for Blacklisting:**

- (i) On receipt of report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is **“NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/ MIS-BRANDED** (As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the particular item of the product/company or firm as deemed fit besides forfeiture of Security deposit
- (ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular item floated by the BPPI until the period of blacklisting is over.
- (iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

### **20.3 BLACKLISTING FOR NON-SUPPLY:**

Notwithstanding various actions and penalties for non-supply and/or delayed supply of the drugs and medicines as stipulated in the terms and conditions of the tender, the BPPI shall take action against the supplier as follows:

- (a) If the supplier fails to execute at least 50% of the ordered quantity as mentioned in a single Purchase order and such part supply for **any three Purchase orders of the same drug**, then the product of the supplier will be blacklisted and becomes ineligible to

participate in any of the tenders for that particular item(s) by BPPI for a period of **2 years** from the date of intimation for blacklisting besides forfeiture of security deposit of that product(s)

- (b) If the supplier supplies more than one item and 50% of such items are blacklisted, the firm is liable to be blacklisted for a period of **2 years from the date of intimation** besides forfeiture of security deposit in full

**20.4.** Purchase orders, if any, already issued before taking any blacklisting action or orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

**20.5.** The blacklisting of particular product or company/firm will be done without prejudice to other penalties which may be imposed as per the conditions of Tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of Land. BPPI will display names of such blacklisted product(s) and company/firm on its website and also circulate the same among other state Government / Central Government and its Drug procurement agencies including respective State Drugs Control Department where the company or firm is located.

## **21. SAVING CLAUSE**

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

## **22.RESOLUTION OF DISPUTES**

- (i) The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract,

## **ARBITRATION AND JURISDICTION**

In the event of any dispute arising out of this Agreement or in connection of this Agreement between the parties hereto, the same will be referred for the arbitration to a sole arbitrator which shall be appointed with the mutual consent of the parties and the arbitration shall be at Delhi only, failing which the parties

will move to the court of competent jurisdiction for the appointment of the sole arbitrator and the parties hereto agree and undertake that the decision of the sole arbitrator either appointed by mutual consent or by the court of competent jurisdiction shall be final and binding on both the parties. The courts at Delhi will only have jurisdiction in connection of this Agreement.

### **23.APPEAL:**

- (i) Any Tenderer aggrieved by the order passed by the Tender Accepting Authority under section 10 of the said Act, may appeal to the Government within ten days from the date of receipt of order and the Government shall dispose the appeal within fifteen days from the date of receipt of such appeal.
- (ii) No Appeal shall be preferred while the tender is in process and until tender is finalized and Notification of award is issued by the BPPI

### **24. CONTACTING THE BPPI BY THE BIDDER:**

- (i) No bidder shall contact the *BPPI* on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.
- (ii) Any effort by a bidder to influence the *BPPI* in the *Purchaser's* bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.
- (ii) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

- (iv) Notwithstanding anything contained in clause (iii) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

## **25 FRAUDULENT AND CORRUPT PRACTICES:**

### **(1)For bidders:**

It is purchaser's policy to require that the bidders, suppliers and contractors and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. *(In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper)* In pursuance of this policy, the purchaser;

- (a) defines, for the purposes of this provision, the terms set forth below as follows:
  - (i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party (*"another party" refers to a public official acting in relation to the procurement process or contract execution*). *In this context, "public official" includes staff and employees of other organizations taking or reviewing procurement decisions.*
  - (ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (*a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution*).
  - (iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party [*"parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non competitive level*].
  - (iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (*a "party" refers to a participant in the procurement process or contract execution*).

(v)“obstructive practice” is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser’s inspection and audit rights provided for under sub-clause (e) below.

(b) will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

(c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub contractors engaged in corrupt, fraudulent, collusive, or coercive practices.

(d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

(e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

**(2) For suppliers:**

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days notice to the Supplier, terminate the Supplier's employment under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Security Deposit apart from other penal actions.

(a) For the purposes of this Sub-Clause:

- (i) “corrupt practice” is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;
- (ii) “fraudulent practice” is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;
- (iii) “collusive practice” is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;
- (iv) “coercive practice” is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;
- (v) “obstructive practice” is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb) acts intended to materially impede the exercise of the purchaser’s inspection and audit rights provided for.

## **26. JURISDICTION**

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.



**FORM OR CERTIFICATE OF SALES TAX VERIFICATION TO BE PRODUCED BY  
AN APPLICANT FROM THE CONTRACT OR OTHER PATRONAGE AT THE  
DISPOSAL OF THE GOVERNMENT OF INDIA.**

**(To be filled up by the applicant)**

01. Name or style in which the applicant :  
is assessed or assessable to Sales Tax  
Addresses or assessment.
  
02. a. Name and address of all companies, :  
firms or associations or persons in  
which the applicant is interested in  
his individual or fiduciary capacity.  
  
b. Places of business of the applicant :  
(All places of business should be  
mentioned).
  
03. The Districts, taluks and divisions in :  
which the applicant is assessed to  
Sales Tax (All the places of business  
should be furnished).
  
04. a. Total contract amount or value of :  
patronage received in the preceding  
three years.

<b>Sl. No.</b>	<b>Financial Year</b>	<b>Turn over</b>
1.	2010 - 2011	
2.	2011 - 2012	
3.	2012 - 2013	

b. Particulars of Sales - Tax for the preceding three years.

<b>Year</b>	<b>Total T.O. be assessed Rs.</b>	<b>Total Tax assessed Rs.</b>	<b>Total Tax paid Rs.</b>	<b>Balance due Rs.</b>	<b>Reasons for balance Rs.</b>
2010-2011					
2011-2012					
2012-2013					

c. If there has been no assessment in :  
any year, whether returns were  
submitted any, if there were, the  
division in which the returns were sent

d. Whether any penal action or :  
proceeding for the recovery of Sales  
Tax is pending.

e. The name and address of Branches :  
if any:

I declare that the above information is correct and complete to the best of my knowledge and belief.

Signature of applicant:

Address:

Date:

**(To be filled up by the Assessing authority)**

In my opinion, the applicant mentioned above has been/ has not been/  
doing everything possible to pay the tax demands promptly and regularly and to  
facilitate the completion of pending proceedings.

Date Seal : Deputy / Asst. Commercial Tax - Officer  
Deputy Asst.

NOTE: A separate certificate should be obtained in respect of each of the place  
of business of the applicant from the Deputy Commercial Tax Officer or  
Assistant Commercial Tax Officer having jurisdiction over that place.

**ANNEXURE-II**  
**Ref. Clause No. 1(n)**

**DECLARATION**

I do hereby declare that I will supply the Drugs and Medicines as per the designs given in enclosures to this Annexure and as per the instructions given in this regard.

Signature of the Tenderer

Name in capital letters with Designation

**Attested by Notary Public.**

**ANNEXURE-II (A)**  
**Ref. Clause No. 4.1 (n) (ii)**

**UNDERTAKING**

I / We do hereby declare that I will supply the Drugs and Medicines by affixing the logo for Secondary / Primary packing for the imported items along with generic Names as per the designs given in enclosures to this Annexure and as per the instructions given in this regard.

Signature of the Tenderer

Name in capital letters with Designation

**Attested by Notary Public.**

**ENCLOSEURE-I TO ANNEXURE-II and II (A) – REFER CLAUSE  
NO.4.1.(n) DESIGN FOR**

Janaushadhi Janaushadhi Janaushadhi Janaushadhi

**ENCLOSURE-II TO ANNEXURE-II and ANNEXURE-II (A)**  
**Ref. Clause No. 4.1. (n) & Clause No: 13**

**DESIGNS FOR LOGORAMS**

**INJECTIONS**

Injection in ampoule form should be supplied with the following logogram which



will distinguish from the normal trade packing.

**LIQUIDS**

Liquid preparations should be in glass bottles with pilfer-proof caps bearing the following logograms:



## **OINTMENTS**

Ointments should be supplied in tubes bearing the following logograms.





**ENCLOSURE-III TO ANNEXURE-II and ANNEXURE-II (A)**

**SPECIMEN LABEL FOR  
OUTER CARTON**

**Batch. : xxxxxxxx**  
**Mfg Date : JUN - 2013**  
**Exp Date : MAY - 2015**

**Quantity Packed: 100x10x10**

**Manufactured by:**



**ANNEXURE-III**

**Ref. Clause No. 4.1 (j),  
7.3(vi)**

**DECLARATION**

I/We M/s.\_\_\_\_\_ represented by its Proprietor / Managing Partner / Managing Director having its Registered Office at \_\_\_\_\_ and its Factory Premises at \_\_\_\_\_ do declare that I/We have carefully read all the conditions of tender in Ref.NoBPPI/DRUG/001 Dt .11.09.2013 for supply of Drugs and Medicines for the year 2013-2015 floated by the Bureau of Pharma Public Sector Undertakings of India , Gurgaon, 122016. and accepts all conditions of the Tender.

I/We declare that we possess the valid licence and GMP Certificate as per revised Schedule-‘M’ issued by the Competent Authority and complies and continue to comply with the conditions laid in Schedule M of Drugs & Cosmetics Act, 1940 and the Rules made thereunder. I/We furnish the particulars in this regard in enclosure to this declaration.

I am/we are aware of the Tender Inviting Authority’s right to forfeit the Earnest Money Deposit and/or Security Deposit and blacklisting me/us for a period of 5 years if, any information furnished by us proved to be false at the time of inspection and not complying the conditions as per Schedule M of the said Act for a period of 5 years.

Signature :

Seal

Name & Address :

**To be attested by the Notary.**

**Enclosure to Annexure – III Clause 4(1)  
(j)**

**DECLARATION FOR COMPLIANCE OF cG.M.P**

01. Name and Address of The Firm :
02. Name of Proprietor / Partner / Director :
03. Name and Designation of qualified personal  
a. Manufacturing  
b. Testing
04. GMP Certificate As per Revised Schedule “M”
05. Details of Licenses Held With Validity :
06. Number of Workers Employed : Ladies  
: Gents  
:
07. Whether Workers Provided with Uniform : Yes / No
08. Whether Medical Examination done  
for the Workers : Yes / No
09. **Hygienic Condition**  
(I) Surrounding : Satisfactory / Not  
Satisfactory (II) Production Areas : Satisfactory /  
Not Satisfactory (III) Other Areas : Satisfactory  
/ Not Satisfactory
10. Provision For Disposal of Waste : Yes / No
11. Heating, Ventilation, Air conditioning System & AHU: Yes/No
12. Whether work Benches Provided in all Yes / No

Working Area

**13. WaterSupply**

(A) Source

DM plant :  
Purified water/R.O.

Water for Injection Plant

(B) Storage Condition : Satisfactory / Not Satisfactory

(C) Testing  
(With reference to Pathogenic Organization) : Yes / No

(D) Cleaning Schedule In Water Supply  
System With Proper Records : Yes / No

(E) Type of Machinery installed as to Semiautomatic  
or Fully Automatic plant for water purification system  
along with cost and whether this is working, and if so  
the flow rate of Pharmaceutical water to must the  
requires preparation :

**14. Air handling system along with list of machine  
and cost of the unit. Separately for sterile and  
non sterile preparation**

Utilities

a. Compressed air/nitrogen

b. Vacuum

c. Steam(boiler) :

15. Whether the pollution control clearance is valid for Air  
and Water and if so the period upto which valid (copy  
of the certificate to be enclosed) :

16. Raw Material Storage Area  
(Storage Facilities / Hygienic Condition) :

(I) Quarantine : Provided / Not Provided

(II) Passed Materials : Provided / Not Provided

(III) Rejected Materials : Provided / Not Provided

17. Finished Product Storage Area  
(Hygienic / Storage) :

(I) Quarantine : Provided / Not Provided

(II) Released Material : Provided / Not Provided

18. Details of Technical Staff

Name

Qualification

Experience

For Manufacturing :

For Testing :

**19. Testing Facilities (List of Equipment to be furnished Separately in the format to meet the bench mark vide Annexure)**

Chemical Method : Yes / No

Instrumental : Yes / No  
(Type of Instrument Provided as indicated in Annexure)

Biological : Yes / No

Micro Biological : Yes / No

Animal Testing : Yes / No

**20. Remarks**

(A) Whether Products Quoted to BPPI are Endorsed in the Licence : Yes / No

(B) Whether the drugs Quoted to BPPI have been Manufactured Earlier (Last 3 Years) : Yes / No

If Yes, Details Like

Sl.No	Date of Manufacturer	Name of the Drug	Batch No.	Batch Size	Date of Release

(C) Production Capacity (Section Wise)

**PRODUCTIONCAPACITY:****TabletSection**

Type of Equipments (1)	No. of Equipments (2)	Production Capacity of all the Equipments in column 2 per shift (3)	No of shift (4)	Production Capacity allotted for BPPI (5)
Planetary mixer				
Fluidized bed drier				
Tray drier				
Mechanical shifter				
Multi mill				
Tablet compression machine				
1) With _____ number of station				
2) With _____ number of station				
3) With _____ number of station				
4) With _____ number of station				
Coating pan.				
Blister Packing machine				
Strip packing machine				

**Capsule Section**

Type of Equipments (1)	No. of Equipments (2)	Production Capacity of all the Equipments in column 2 per shift (3)	No of shift (4)	Production Capacity allotted for BPPI (5)
Double cone blender				
Automatic capsule filling machine				

<b>Type of Equipments</b>  <b>(1)</b>	<b>No. of Equipments</b>  <b>(2)</b>	<b>Production Capacity of all the Equipments in column 2 per shift</b>  <b>(3)</b>	<b>No of shift</b>  <b>(4)</b>	<b>Production Capacity allotted for BPPI</b>  <b>(5)</b>
Semi automatic Capsule filling machine				
Hand filling machine				
Blister packing machine				
strip packing machine				

### **ParenteralSection**

<b>Type of Equipments</b>  <b>(1)</b>	<b>No. of Equipments</b>  <b>(2)</b>	<b>Production Capacity of all the Equipments in column 2 per shift</b>  <b>(3)</b>	<b>No of shift</b>  <b>(4)</b>	<b>Production Capacity allotted for BPPI</b>  <b>(5)</b>
Small volume Parenteral				
Mixing Vessel				
Laminar Flow unit				
Filtration unit				
Ampoule filling machine (with No of head)				
Vial filling Machine (with No of head)				
Vial sealing machine				
Powder filling machine				
Autoclave for terminal Sterilization				
Ampoule labeling machine				
Vials labeling machine				



### **Large Volume Parenterals**

Type of Equipments (1)	No. of Equipments (2)	Production Capacity of all the Equipments in column 2 per shift (3)	No of shift (4)	Production Capacity allotted for BPPI (5)
Mixing vessel				
Filtration Unit.				
Filling Machine Autoclave for terminal Sterilization				
Labeling Machine				

### **Ointment/Cream**

Type of Equipments (1)	No. of Equipments (2)	Production Capacity of all the Equipments in column 2 per shift (3)	No of shift (4)	Production Capacity allotted for BPPI (5)
Stream jacket vessel for mixing				
Ointment/cream filling machine				

### **Liquid Section**

Type of Equipments (1)	No. of Equipments (2)	Production Capacity of all the Equipments in column 2 per shift (3)	No of shift (4)	Production Capacity allotted for BPPI (5)
Bottle washing machine				
SS tank with capacity				
Filter press				
Colloidal mill				
Bottle Filling Machine				
Labeling Machine				

**External Preparation**

Type of Equipments  (1)	No. of Equipments  (2)	Production Capacity of all the Equipments in column 2 per shift  (3)	No of shift  (4)	Production Capacity allotted for BPPI  (5)
Mixing Vessel				
Filling machine				
Labeling machine				

(D) Any, Not Of Standard Quality : Yes / No  
Reports Of Product Quoted/  
Approved By BPPI  
(If Not, Nil Statement)

(E) Any Prosecution After : Yes / No  
Submission of Tender Documents.  
(If Not, Nil Statement)

(F) Chances Of Cross Contamination : Yes / No  
at Raw Materials/In Process/  
Finished Product Stages And Steps/Facilities

(G) Validation of Equipments done : Yes / No

(H) Cleaning Schedule

(I) For Premises :

(II) For Equipments :

(I) Adverse Reaction, If Any and :  
Reported

Sl.No.	Description	Remarks
1	Whether any drug(s) manufactured by the tenderer has / have been recalled during last five years? If yes given details	

Sl.No.	Description	Remarks
2	What are the results of investigations on the recalled drug(s)?	
3	What action have been taken to prevent recurrence of recall of drug(s) on that particular account?	

(J) Complaints Received If Any :  
and Steps taken.

Sl.No.	Description	Remarks
1	Whether any drug(s) manufactured by the tenderer has / have been recalled during last five years? If yes given details	
2	What are the results of investigations on the recalled drug(s)?	
3	What action have been taken to prevent recurrence of recall of drug(s) on that particular account?	

Signature and Seal of  
Proprietor / Partner / Director

To be attested by the Notary.

**Annexure**

<b>Sl.</b>	<b>Name of the Instruments</b>	<b>No. of Instruments</b>	<b>Cost of Instruments</b>	<b>Whether it is in working condition</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>(5)</b>
1	Analytical Balance			
2	Infra Red Spectrometer			
3	Karl Fisher Tritator			
4	Melting Point			
5	Brookfield Viscometer			
6	Polarimeter			
7	Autoclave			
8	Refractometer			
9	Sampling Booth			
10	UV-Vis Spectrometer			
11	HPLC			
12	Muffle Furnace			
13	Fuming Cupboard			
14	Micrometer			
15	Dissolution Tester			
16	Disintegration Tester			
17	Friability Tester			
18	Vernier Calipers			
19	IR Balance			

<b>Sl.</b>	<b>Name of the Instruments</b>	<b>No. of Instruments</b>	<b>Cost of Instruments</b>	<b>Whether it is in working condition</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>(5)</b>
20	Hardness Tester			
21	Leak Test Apparatus			
22	Laminar Air Flow			
23	BOD Incubator			
24	Vacuum oven			
25	Bulk Density Apparatus			
26	Water Activity Meter			
27	Anaerobic System			
28	Gas Chromatograph			
29	LAL Kit			
30	Sterility Test Kit			
31	Particle Counter			
32	Air Sampler			
33	Flame Photometer			
34	Tap Density Tester			

**DECLARATION**

I \_\_\_\_\_ Managing Director /  
Director / Partner / Proprietor of M/s. \_\_\_\_\_  
having its manufacturing or import unit / registered office at  
\_\_\_\_\_ do hereby declare that we  
have not been blacklisted either by any State Government or Central Government  
Organization or its drug procurement agencies for the following products quoted  
in the tender. We are eligible to participate in the tender ref. no. BPPI/DRUG/001 Dt  
.11.09.2013 for the following products.

Sl. No.	Drug Code	Name of the Drug

M/s. \_\_\_\_\_

Company seal

**To be attested by the Notary.**

**DETAILS OF E.M.D. SUBMITTED**

We herewith submit the E.M.D. of Rs. \_\_\_\_\_ in the form of  
Demand Draft bearing No. \_\_\_\_\_ Dated: \_\_\_\_\_ drawn on  
\_\_\_\_\_ Bank \_\_\_\_\_ Branch  
in favour of BPPI for the following items of drugs.

<b>Sl. No.</b>	<b>Drug code*</b>	<b>Name of the Drug</b>	<b>Amount of E.M.D.</b>
		<b>Total</b>	

\* in ascending order as in **Annexure-IX**.

**Signature & Seal**

**NOTARISED UNDERTAKING**

**(In 20- Rupees stamp paper)**

I \_\_\_\_\_, S/o \_\_\_\_\_, Proprietor / Partner /  
Managing Director of \_\_\_\_\_ (Proprietary  
Concern / Firm / Company Ltd.) execute this Undertaking for myself and on behalf  
of \_\_\_\_\_ (Proprietary Concern / Firm / Company Ltd.).

3. And whereas, in pursuant to the conditions in Clause Nos. 7.2 & 7.3(viii) of  
the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting  
Authority in case of violation of any of the conditions and for non-performance of  
the obligation under tender document.



M/s \_\_\_\_\_

for Self and Firm / Company Ltd.

Signature and Seal

Witness:-

(1)

(2)

**PROFORMA FOR PERFORMANCE STATEMENT**  
**(FOR A PERIOD OF LAST 3 YEARS)**

Name of firm\_\_\_\_\_

Sl.	Name of the product	Year	No. of batches manufactured / imported & supplied.	Batch No.	Name and full address of the purchaser
	1	2	3	4	5
1.					
2.					
3.					

Note : Proof for the manufacturing (BMR) / importing of the drug quoted to be produced.

Signature and seal of the Tenderer\_\_\_\_\_

**ANNUAL TURNOVER STATEMENT**

The Annual Turnover of M/s. \_\_\_\_\_ for the past three years are given below and certified that the statement is true and correct.

---

Sl.No.	Financial Year	Turnover in Lakhs (Rs)
1.	2010-2011	-
2.	2011-2012	-
3.	2012-2013	-

---

Total	-	Rs. _____ Lakhs.
-------	---	------------------

---

Average turnover per annual - Rs. \_\_\_\_\_ Lakhs.

Date:

Seal:

Signature of Auditor/  
Chartered Accountant  
(Name in Capital)

**TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES FOR THE YEAR 2013-2015**

1. Every Consignment of Blood and related products should be certified to be  
(a) AIDS Free (b) Hepatitis B Free
2. Strips of Aluminum foils refer to gauge 04.
3. Aluminum foils as back material for blisters refer to gauge 025.
4. The rigid PVC used in blister packing should be of not less than 250 micron
5. All glass bottles should be new neutral glass.
6. Ointments should be packed in liquidized Aluminum Tubes.
7. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
8. Specification of outer cartons are as given in the Schedule (Annexure-X)
9. In case of any conflict between Carton specifications and packets per carton specification (Last column of this table), the specification of the packets / carton shall prevail.
10. All tablets should have a score line.
11. All plastic containers should be made of virgin grade plastics.
12. All plastic jars above 450Gms / ml should carry an inner plastic lid.
13. Injection in vials should have a flip of seals.
14. The strips shall be aluminum strip / blisters with aluminum foil back.
15. The minimum diameters of each tablets should be of 6.4mm
16. The outer carton should be of white board with a minimum of 300 GSM with laminated packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 450GSM.

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016**

**Annexure - IX**

Ref Clause 8.1 & 8.2, 3(iv), 4.1(a), 7.1(a)

**TENDER FOR THE SUPPLY OF MEDICINES FOR THE YEAR 2013-2015**

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx tender Qty in units	Packing per carton specification	EMD Value Rs.
		<b>ANALGESIC/ ANTI-INFLAMMATORY/ MUSCLOSKELETAL DISORDER</b>				
1	1	Aceclofenac + Paracetamol (100 mg + 500mg) Tablets	10x10	52,500	100 X 10X10's	52,000
2	2	Aceclofenac 100 mg Tablets	10x10	21,000	100 X 10X10's	25,000
3	3	Aceclofenac Gel	30 g tubes	105,000	200 X 30GM	27,000
4	4	Acetaminophen + Tramadol Hydrochloride (325 mg + 37.5 mg) film coated Tablets	10x10	21,000	100 X 10X10's	17,000
5	5	Asprin 150 mg Tab	14x10	52,500	100 X 14X10's	21,000
6	6	Chlorzoxazone + Diclofenac + Paracetamol (500 mg + 50 mg + 500 mg) film coated	10x10	21,000	100 X 10X10's	31,000
7	7	Diclofenac Gel	15 g	210,000	200 X 15 GM	32,000
8	8	Diclofenac Sodium + Serratiopeptidase (50mg + 10mg) Tab	10x10	21,000	100 X 10X10's	38,000
9	9	Diclofenac Sodium (SR) 100 mg Tab	10x10	105,000	100 X 10X10's	54,000
10	10	Diclofenac Sodium 25mg per ml Inj.	3 ml	105,000	100X10X3 ML	5,000
11	11	Diclofenac Sodium 50 mg Tab	10x10	105,000	100 X 10X10's	34,000
12	12	Etoricoxib 120mg Tab	10x10	21,000	100 X 10X10's	96,000
13	13	Etoricoxib 90mg Tab	10x10	21,000	100 X 10X10's	77,000
14	14	Ibuprofen + Paracetamol (400 mg + 325 mg) Tab	10x10	105,000	100 X 10X10's	86,000
15	15	Ibuprofen 200mg film coated Tablets	10x10	21,000	100 X 10X10's	8,000
16	16	Ibuprofen 400 mg film coated Tablets	10x10	52,500	100 X 10X10's	35,000
17	17	Indomethacin 25 mg Cap	10x10	10,500	100 X 10X10's	6,000
18	18	Methyl Salicylate Oint.(Eutheria)	20 g	105,000	200 X 20GM	42,000
19	19	Nimesulide + Paracetamol (100 mg + 500mg) Tab	10x10	105,000	100 X 10X10's	129,000
20	20	Nimesulide 100 mg Tab	10x10	52,500	100 X 10X10's	21,000
21	21	Paracetamol + Diclofenac Sodium (500 mg + 50 mg) Tab	10x10	105,000	100 X 10X10's	71,000

22	22	Paracetamol 125 mg / 5 ml Syrup	60 ml bottles	105,000	50 X60 ML	14,000
23	23	Paracetamol 500mg Tab	10x10	210,000	100 X 10X10's	79,000
24	24	Pentazocine 30 mg/ ml Inj.	1 ml	52,500	50x10x1 ml	3,000
25	25	Serratiopeptidase 10 mg Tab	10x10	10,500	100 X 10X10's	14,000
26	26	Tramadol 100 mg Inj.	2ml	105,000	50x10x2 ml	28,000
27	27	Tramadol 50 mg Inj.	1ml	52,500	50x10x1 ml	7,000
28	28	Tramadol 50 mg Tab	10x10	21,000	100 X 10X10's	29,000
<b>ANTIBIOTICS</b>				-		-
29	29	Acyclovir 400 mg film coated Tablets	10x10	21,000	100 X 10X10's	65,000
30	30	Amikacin 100mg inj.	Vial	105,000	20x50x2 ml	10,000
31	31	Amikacin 250mg inj.	Vial	52,500	20x50x2 ml	7,000
32	32	Amikacin 500mg inj.	Vial	157,500	20x50x2 ml	29,000
33	33	Amoxycillin + Bromhexine (250 mg + 8 mg) Caps	10x10	52,500	100 X 10X10's	207,000
34	34	Amoxycillin + Bromhexine (500 mg + 8 mg) Caps	10x10	52,500	100 X 10X10's	374,000
35	35	Amoxycillin + Clavulanic acid (1000 mg + 200mg) Ini.	Vial with WFI	105,000	20X10 ML	129,000
36	36	Amoxycillin + Clavulanic acid (200 mg+28.5 mg /5ml) Dry Syrup	30 ml bottles	157,500	2X50X30 ML	106,000
37	37	Amoxycillin + Clavulanic acid (250 mg + 50 mg) Ini.	Vial with WFI	52,500	30x10 ml	31,000
38	38	Amoxycillin + Clavulanic acid (500 mg + 100mg) Ini.	Vial with WFI	52,500	30x10 ml	53,000
39	39	Amoxycillin + Clavulanic acid (500 mg + 125 mg) film coated Tablets	6x10	52,500	50x10x6's	367,000
40	40	Amoxycillin + Cloxacillin (250 mg + 250 mg) Caps	10x10	52,500	100 X 10X10's	161,000
41	41	Amoxycillin + Di-Cloxacillin (250 mg + 250 mg) Caps	10x10	21,000	100 X 10X10's	96,000
42	42	Amoxycillin 125 mg Kid Tabs	10x10	52,500	100 X 10X10's	80,000
43	43	Amoxycillin 125mg/ 5ml Dry Syrup	60 ml bottles	105,000	50X60 ML	25,000
44	44	Amoxycillin 250 mg Caps	10x10	21,000	100 X 10X10's	42,000
45	45	Amoxycillin 500 mg Caps	10x10	52,500	100 X 10X10's	187,000
46	46	Ampicillin 500mg inj.	Vial	21,000	24X25 VIAL	2,000
47	47	Azithromycin (100mg/ 5ml) Syrup	15 ml bottles	105,000	5X30X15 ML	22,000

48	48	Azithromycin 100 mg DT Tab	10x10	52,500	100 X 10X10's	228,000
49	49	Azithromycin 250 mg film coated Tablets	10x10	52,500	100 X 10X10's	339,000
50	50	Azithromycin 500 mg film coated Tablets	10x10	105,000	100 X 10X10's	1,322,000
51	51	Cefadroxil 250 mg film coated Tablets	10x10	21,000	100 X 10X10's	47,000
52	52	Cefadroxil 500 mg film coated Tablets	10x10	52,500	100 X 10X10's	210,000
53	53	Cefixime (50 mg/ 5ml) Dry Syrup	30 ml bottles	105,000	50X30 ML	38,000
54	54	Cefixime 100mg film coated Tablets	10x10	52,500	100 X 10X10's	339,000
55	55	Cefixime 200mg film coated Tablets	10x10	105,000	100 X 10X10's	1,066,000
56	56	Cefoperazone + Sulbactam ( 1g + 1g) Inj.	Vial & wfi	52,500	20X5 VIAL	113,000
57	57	Cefoperazone + Sulbactam (500 mg + 500 mg) Inj.	Vial & wfi	105,000	20X10 VIAL	113,000
58	58	Cefoperazone 1 gm Inj.	Vial	52,500	20X10 VIAL	27,000
59	59	Cefotaxime Sodium & Sulbactam Sodium (1g + 500 mg) Inj.	Vial & wfi	52,500	20X10 VIAL	21,000
60	60	Cefotaxime Sodium & Sulbactam Sodium (250 mg + 125 mg) Inj.	Vial & wfi	21,000	30X10 VIAL	3,000
61	61	Cefotaxime Sodium & Sulbactam Sodium (500 mg + 250 mg) Inj.	Vial & wfi	21,000	30X10 VIAL	5,000
62	62	Cefotaxime Sodium 1000mg Inj.	Vial & wfi	105,000	20X10 VIAL	32,000
63	63	Cefotaxime Sodium 250 mg Inj.	Vial & wfi	21,000	30X10 VIAL	3,000
64	64	Cefotaxime Sodium 500 mg Inj.	Vial & wfi	21,000	30X10 VIAL	4,000
65	65	Cefpodoxime 100 mg DT	10x10	52,500	100 X 10X10's	343,000
66	66	Cefpodoxime 200 mg film coated Tablets	10x10	105,000	100 X 10X10's	1,317,000
67	67	Ceftazadime 1000 mg Inj.	Vial & wfi	21,000	20X10	22,000
68	68	Ceftazadime 250 mg Inj.	Vial & wfi	21,000	30X10	7,000
69	69	Ceftazadime 500 mg Inj.	Vial & wfi	52,500	30X10	30,000
70	70	Ceftriaxone + Sulbactam (1000 mg + 500 mg) Inj.	Vial & wfi	52,500	20X10	37,000
71	71	Ceftriaxone + Tazobactam 1000 mg + 125 mg Inj.	Vial & wfi	21,000	20X10	10,000
72	72	Ceftriaxone + Tazobactam 250 mg + 31.25 mg Inj.	Vial & wfi	21,000	30X10	5,000
73	73	Ceftriaxone +Sulbactam (250 mg + 125 mg)	Vial & wfi	52,500	30X10	10,000
74	74	Ceftriaxone +Sulbactam (500 mg + 250 mg)	Vial & wfi	52,500	30X10	25,000

75	75	Ceftriaxone 1 g Inj.	Vial & wfi	157,500	20X10	91,000
76	76	Ceftriaxone 250 mg Inj.	Vial & wfi	52,500	30X10	13,000
77	77	Ceftriaxone 500 mg Inj.	Vial & wfi	52,500	30X10	18,000
78	78	Cefuroxime Axetil 250 mg film coated Tablets	10x10	52,500	100 X 10X10's	833,000
79	79	Cefuroxime Axetil 500mg film coated Tablets	10x10	21,000	100 X 10X10's	660,000
80	80	Cephalexin 125 mg DT	10x10	52,500	100 X 10X10's	87,000
81	81	Cephalexin 250 mg Caps	10x10	21,000	100 X 10X10's	56,000
82	82	Cephalexin 500 mg Caps	10x10	52,500	100 X 10X10's	255,000
83	83	Ciprofloxacin + Tinidazole (250 mg + 300 mg) film coated Tablets	10x10	21,000	100 X 10X10's	54,000
84	84	Ciprofloxacin + Tinidazole (500 mg + 600 mg) film coated Tablets	10x10	52,500	100 X 10X10's	265,000
85	85	Ciprofloxacin 250 mg film coated Tablets	10x10	21,000	100 X 10X10's	36,000
86	86	Ciprofloxacin 500 mg film coated Tablets	10x10	157,500	100 X 10X10's	523,000
87	87	Clotrimazole 1% w/w Oint.	15 g tubes	105,000	200 X 15 GM	11,000
88	88	Co-trimoxazole (Sulphamethoxazole 200mg + Trimethoprim 40mg / 5ml) Susp	50 ml bottle	105,000	50X50 ML	15,000
89	89	Co-trimoxazole -DS (160 mg + 800 mg) Tabs	10x10	105,000	100 X 10X10's	167,000
90	90	Co-trimoxazole- Pead. (20 mg + 100 mg) Tabs	10x10	21,000	100 X 10X10's	5,000
91	91	Co-trimoxazole –SS (80 mg + 400 mg)	10x10	52,500	100 X 10X10's	44,000
92	92	Doxycycline 100 mg Caps	10x10	52,500	100 X 10X10's	58,000
93	93	Erythromycin Stearate 250 mg film coated Tablets	10x10	52,500	100 X 10X10's	120,000
94	94	Gentamycin Sulphate 80 mg/ 2ml Inj.	2 ml	21,000	20X50X2 ML	1,000
95	95	Levofloxacin 250 mg film coated Tablets	10x10	21,000	100 X 10X10's	74,000
96	96	Levofloxacin 500 mg film coated Tablets	10x10	21,000	100 X 10X10's	144,000
97	97	Meropenem 1gm Inj.	Vial & wfi	52,500	30X 5 VIALS	616,000
98	98	Norfloxacin + Tinidazole (400 mg + 600 mg) film coated Tablets	10x10	10,500	100 X 10X10's	23,000
99	99	Norfloxacin 400 mg film coated Tablets	10x10	10,500	100 X 10X10's	15,000
100	100	Ofloxacin + Ornidazole (200 mg + 500 mg) film coated Tablets	10x10	21,000	100 X 10X10's	91,000
101	101	Ofloxacin 200 mg film coated Tablets	10x10	21,000	100 X 10X10's	54,000



102	102	Ofloxacin 400 mg film coated Tablets	10x10	52,500	100 X 10X10's	257,000
103	103	Piperacillin + Tazobactam 4 g + 0.5 mg Inj.	Vial & wfi	52,500	15X5 VIALS	31,000
104	104	Roxithromycin (50 mg/ 5ml) Susp.	30 ml bottles	21,000	100X30 ML	8,000
105	105	Roxithromycin 150 mg film coated Tablets	10x10	21,000	100 X 10X10's	68,000
106	106	Roxithromycin 300 mg film coated Tablets	10x10	10,500	100 X 10X10's	65,000
107	107	Tinidazole 300 mg film coated Tablets	10x10	10,500	100 X 10X10's	7,000
108	108	Tinidazole 500 mg film coated Tablets	10x10	10,500	100 X 10X10's	11,000
109	109	Vancomycin 500 mg	Vial & wfi	21,000	20X10	9,000
<b>ANTI INFECTIVES (TOPICALS)/ ANTIFUNGAL/ SKIN OINTMENT</b>				-		-
110	110	Adapalene 0.1 % w/v Ointment	15 g tubes	21,000	200 X 15 GM	2,000
111	111	Application Benzyl Benzoate 25 % w/w Lotion	100 ml	52,500	100X100 ML	10,000
112	112	Beclomethasone + Clotrimazole + Gentamycin (0.025%+1.0%+0.1% w/w) Cream	15 g tubes	52,500	200 X 15 GM	13,000
113	113	Beclomethasone + Neomycin (0.025% + 0.5% w/w) Cream	15 g tubes	52,500	200 X 15 GM	10,000
114	114	Beclomethasone Dipropionate 0.025% w/v Oint.	15 g tubes	21,000	200 X 15 GM	2,000
115	115	Calamine Lotion	100 ml bottles	31,500	100X100 ML	10,000
116	116	Chlorhexidine Gluconate 5% Solution	500 ml bottles	21,000	20X500 ML	-
117	117	Chlorhexidine Gluconate 0.2% Mouth Wash	150 ml bottles	31,500	100X150 ML	11,000
118	118	Clobetasol Propionate 0.05 % w/w Cream	15 g tubes	31,500	200 X 15 GM	9,000
119	119	Fluconazole 150 mg film coated Tablets+C158+C158	10x10	42,000	100 X 10X10's	137,000
120	120	Fusidic Acid 2 % w/v Cream	10 g tubes	21,000	200 X 10GM	10,000
121	121	Glutaraldehyde 2% w/v Solution	500 ml bottles	31,500	20X500 ML	25,000
122	122	Ketoconazole 2 % w/w Lotion	100 ml bottles	31,500	100X100 ML	13,000
123	123	Lignocaine 2% w/w Ointment	30 g tubes	31,500	200 X 30GM	7,000
124	124	Povidone Iodine 5% w/w Ointment	250 gm tubes	21,000	24X250 GM	37,000
125	125	Povidone Iodine 5%w/w Ointment	15 gm tubes	157,500	200 X 15 GM	21,000
126	126	Povidone Iodine 10 % Solution	500 ml bottles	21,000	20X500 ML	44,000
127	127	Povidone Iodine 5 % Solution	100 ml bottles	31,500	100X100 ML	5,000

128	128	Povidone Iodine 5 % Solution	500 ml bottles	21,000	20X500 ML	27,000
129	129	Povidone Iodine 7.5% Solution	500 ml bottles	10,500	20X500 ML	17,000
130	130	Ravlon Solution (Chlorhexidine + Cetramide ) (1.5 % w/v + 3% w/v) Solution	100 ml bottles	21,000	100X100 ML	10,000
131	131	Silver Sulphadiazine 1 % w/w Cream	20 gm tubes	105,000	200 X 20GM	14,000
132	132	Silver Sulphadiazine 1 % w/w Cream	500 gm jars	21,000	15X500 GMS	60,000
<b>ANTIDIABETIC DRUGS</b>				-		-
133	133	Glibenclamide 2.5 mg Tabs (Scored Oval)	10x10	21,000	100 X 10X10's	6,000
134	134	Glibenclamide 5 mg Tabs (Scored Oval)	10x10	21,000	100 X 10X10's	8,000
135	135	Gliclazide 40 mg Tabs	10x10	21,000	100 X 10X10's	4,000
136	136	Gliclazide 80 mg Tabs	10x10	21,000	100 X 10X10's	4,000
137	137	Glimeperide 1mg Tab	10x10	105,000	100 X 10X10's	127,000
138	138	Glimeperide 2mg Tabs	10x10	105,000	100 X 10X10's	191,000
139	139	Glimeperide 1mg + Metformin 500mg + Pioglitazone 15mg	10x10	21,000	100 X 10X10's	25,000
140	140	Glimeperide 2mg + Metformin 500mg + Pioglitazone 15mg	10x10	21,000	100 X 10X10's	26,000
141	141	Glipizide 5 mg Tabs	10x10	21,000	100 X 10X10's	6,000
142	142	Insulin Injection (Human) (40iu/ml)	10 ml Vial	42,000	10X5X10 VIALS	10,000
143	143	Insulin Injection {Insulin Human (Soluble 30% & Isophane 70%) 40iu/ml}	10 ml Vial	21,000	10X5X10 VIALS	5,000
144	144	Metformin Hydrochloride 1000 mg SR Tabs	10x10	31,500	100 X 10X10's	53,000
145	145	Metformin Hydrochloride 500mg Tabs	10x10	210,000	100 X 10X10's	195,000
146	146	Pioglitazone 15 mg Tabs	10x10	21,000	100 X 10X10's	4,000
147	147	Pioglitazone 30 mg Tabs	10x10	21,000	100 X 10X10's	4,000
148	148	Pioglitazone 15 mg Tabs + Glimeperide 1mg	10x10	21,000	100 X 10X10's	4,000
149	149	Pioglitazone 15 mg Tabs + Glimeperide 2mg	10x10	21,000	100 X 10X10's	6,000
150	150	Pioglitazone 15 mg Tabs + Metformin 500mg	10x10	21,000	100 X 10X10's	6,000
<b>ANTI-MIGRAINE DRUGS</b>				-		-
151	151	Dihydroergotamine 1 mg film coated Tablets	10x10	10,500	100 X 10X10's	2,000
<b>ANTI-NEOPLASTIC DRUGS</b>				-		-

152	152	Bleomycin 15 mg Inj.	Vial	52,500	As per standard packing	52,000
153	153	Cisplatin 10 mg Inj.	Vial	52,500	As per standard packing	52,000
154	154	Cisplatin 50 mg Inj.	Vial	52,500	As per standard packing	52,000
155	155	Doxorubicin 10 mg Inj.	Vial	52,500	As per standard packing	52,000
156	156	Doxorubicin 50 mg Inj.	Vial	52,500	As per standard packing	52,000
157	157	Etoposide 100 mg Caps	10x10	10,500	100 X 10X10's	3,000
158	158	Etoposide 100 mg/5ml Inj.	Vial	52,500	As per standard packing	52,000
159	159	Gemcitabine 1000 mg Inj.	Vial	52,500	As per standard packing	52,000
160	160	Gemcitabine 200 mg Inj.	Vial	52,500	As per standard packing	78,000
161	161	Medroxyprogesterone Acetate 10 mg film coated Tablets	10x10	10,500	100 X 10X10's	3,000
162	162	Raloxifene 60 mg Tab	10x10	10,500	100 X 10X10's	3,000
163	163	Tamoxifen Citrate 10 mg Tab	10x10	10,500	100 X 10X10's	2,000
164	164	Tamoxifen Citrate 20 mg Tab	10x10	10,500	100 X 10X10's	2,000
<b>I.V.FLUIDS</b>				-		-
165	165	Ciprofloxacin (2mg/ml) Infusion	100 ml bottles	52,500	100X100 ML	12,000
166	166	Dextrose 10% (10D)	500 ml bottles	52,500	20X500 ML	17,000
167	167	Dextrose 5% (5 D)	500 ml	52,500	20X500 ML	14,000
168	168	Glucose Normal Saline (DNS)	500 ml bottles	52,500	20X500 ML	14,000
169	169	Levofloxacin 500 mg Infusion	100 ml bottles	52,500	100X100 ML	28,000
170	170	Mannitol 20%	100 ml bottles	52,500	100X100 ML	25,000
171	171	Mannitol 20%	350 ml	52,500	20x350 ml	52,000
172	172	Metronidazole 5 mg / ml Infusion	100 ml	52,500	100X100 ML	10,000
173	173	Normal Saline (NS)	500 ml	52,500	20X500 ML	14,000
174	174	Plasma Volume Expander (Gelatin Base)	500 ml	52,500	20X500 ML	92,000
175	175	Ringer Lactate (RL)	500 ml	52,500	20X500 ML	25,000
176	176	Water for Injection	5ml Amp	105,000	30x10x5 ml	4,000
<b>GASTROINTESTINAL TRACT/ ANTHELMINTICS</b>				-		-

177	177	Albendazole (200 mg/ 5ml) Syrup	10 ml bottles	105,000	20x10x10 ml	10,000
178	178	Albendazole + Ivermectin (400 mg + 6mg) Tab	10x1 Tab	52,500	50x10x1 tab	13,000
179	179	Albendazole 400mg Tabs	10x10	52,500	100 X 10X10's	111,000
180	180	Bisacodyl 5mg Tablets	10x10	21,000	100 X 10X10's	15,000
181	181	Cyproheptadine HCl + Tricholine Citrate (2 mg + 275 mg) Syrup	200 ml bottles	10,500	50X200 ML	3,000
182	182	Dicyclomine + Mefenamic Acid (20 mg + 250 mg) Tabs	10x10	21,000	100 X 10X10's	22,000
183	183	Dicyclomine 10 mg Tabs	10x10	52,500	100 X 10X10's	16,000
184	184	Dicyclomine HCl. + Paracetamol (20 mg + 500 mg) Tabs	10x10	52,500	100 X 10X10's	27,000
185	185	Diethylcarbamazine citrate 100 mg film coated Tablets	10x10	10,500	100 X 10X10's	4,000
186	186	Domperidone 10 mg Tabs	10x10	21,000	100 X 10X10's	7,000
187	187	Domperidone 5 mg. / 5 ml Syrup	30 ml bottles	52,500	200X30 ML	6,000
188	188	Dried Al(OH) <sub>3</sub> + Mg(OH) <sub>2</sub> + Simethicone (250 + 250 + 50) mg Tabs	10x10	52,500	100 X 10X10's	42,000
189	189	Enzyme Syrup	200 ml bottles	157,500	50X200 ML	100,000
190	190	Enzyme film coated Tablets	10x10	157,500	100 X 10X10's	194,000
191	191	Famotidine 20 mg Tabs	10x10	10,500	100 X 10X10's	3,000
192	192	Famotidine 40 mg Tabs	10x10	52,500	100 X 10X10's	30,000
193	193	Furazolidone 100 mg Tabs	10x10	10,500	100 X 10X10's	3,000
194	194	Hyoscine Butyl Bromide 10 mg film coated Tablets	10x10	10,500	100 X 10X10's	2,000
195	195	Ispagula Husk Powder	200 g Pack	52,500	30x200 gms	12,000
196	196	Lactobacillus 60 million spores Tabs	10x10	10,500	100 X 10X10's	8,000
197	197	Lactulose 10 g/15 ml Syrup	100 ml bottles	31,500	100X100 ML	25,000
198	198	Aluminium Hydroxide + Magnesium Hydroxide (250+250mg / 5ml) Susp	170 ml	105,000	50X170 ML	21,000
199	199	Metoclopramide 10 mg Tabs	10x10	10,500	100 X 10X10's	4,000
200	200	Metoclopramide Inj.	2 ml	52,500	100X10X2 ML	3,000
201	201	Metronidazole 200 mg film coated Tablets	10x10	10,500	100 X 10X10's	4,000
202	202	Metronidazole 400 mg film coated Tablets	10x10	21,000	100 X 10X10's	14,000
203	203	Misoprostol 200 mcg film coated Tablets	4x10	10,500	100X4X10	11,000

204	204	Norfloxacin + Metronidazole (100 mg+100 mg/5 ml) Syrup	30 ml bottles	21,000	10X10X30 ML	3,000
205	205	Ofloxacin+ Metronidazole (50 mg + 100mg/5 ml) Syrup	30 ml bottles	10,500	10X10X30 ML	4,000
206	206	Omeprazole + Domperidone (20 mg + 10 mg) Caps	10x10	21,000	100 X 10X10's	26,000
207	207	Omeprazole 20 mg film coated Tablets	10x10	105,000	100 X 10X10's	111,000
208	208	Ondansetron 2 mg/ml Inj.	2 ml	21,000	50X10X2 ML	1,000
209	209	Ondansetron 4 mg Tabs	10x10	21,000	100 X 10X10's	25,000
210	210	Ornidazole 500 mg film coated Tablets	10x10	21,000	100 X 10X10's	42,000
211	211	Pantoprazole 20 mg film coated Tablets	10x10	21,000	100 X 10X10's	25,000
212	212	Pantoprazole 40 mg film coated Tablets	10x10	157,500	100 X 10X10's	250,000
213	213	Pantoprazole 40 mg/ 10ml Inj.	Vial	52,500	20X10X10	8,000
214	214	Rabeprazole + Domperidone SR (20 mg + 30 mg) film coated Tablets	10x10	52,500	100 X 10X10's	193,000
215	215	Rabeprazole 20 mg film coated Tablets	10x10	21,000	100 X 10X10's	44,000
216	216	Ranitidine (50 mg/ 2ml) Inj.	2ml	21,000	100X10X2 ML	-
217	217	Ranitidine HCl. 150 mg film coated Tablets	10x10	210,000	100 X 10X10's	131,000
218	218	Ranitidine HCl. 300 mg film coated Tablets	10x10	52,500	100 X 10X10's	60,000
<b>VITAMINS</b>				-		-
219	219	Calcium + Vitamin D <sub>3</sub> 250iu film coated Tablets	10x10	21,000	100 X 10X10's	12,000
220	220	Calcium + Vitamin D <sub>3</sub> 500iu film coated Tablets	10x10	157,500	100 X 10X10's	167,000
221	221	Calcium Citrate + Vitamin D <sub>3</sub> (100 mg + 125 iu) Syrup	150 ml bottles	52,500	50X150ML	25,000
222	222	Calcium with Minerals Suspension	150ml	21,000	50X150ML	6,000
223	223	Doxylamine Succinate + Pyridoxine + Folic Acid (10 mg + 10 mg + 2.5 mg) film coated Tablets	10x10	21,000	100 X 10X10's	32,000
224	224	Folic Acid 5mg Tabs	10x10	21,000	100 X 10X10's	9,000
225	225	Iron + Folic Acid Syrup	200 ml bottles	31,500	50X200 ML	22,000
226	226	Iron, Folic Acid & Zinc (Carbonil Iron) Caps	15 x10	52,500	50X15X10	73,000
227	227	Polyvitamin (Prophylactic) NFI film coated Tablets	10x10	105,000	100 X 10X10's	68,000
228	228	Tonic Iron, Folic Acid & Zinc (Carbonil Iron) Syrup	200 ml bottles	52,500	50X200 ML	24,000
229	229	Vitamin + Iron Tonic Syrup	100 ml bottles	21,000	100X100 ML	7,000

230	230	Vitamin B Complex with Vitamin C & Zinc (Cebexin -Z) Caps	10x10	105,000	100 X 10X10's	121,000
231	231	Vitamin B-Complex (Prophylactic) film coated Tablets	10x10	52,500	100 X 10X10's	14,000
232	232	Vitamin B-Complex NFI Syrup	200 ml bottles	21,000	50X200 ML	7,000
233	233	Vitamin-C Chewable 500mg Tablet	10x10	52,500	100 X 10X10's	5,000
<b>RESPIRATORY SYSTEM &amp; ANTI-ALLERGICS</b>				-		-
234	234	Budesonide 0.25 mg/ml Respule	2 ml	31,500	100X10X2 ML	1,000
235	235	Budesonide 0.5 mg/ml Respule	2 ml	31,500	100X10X2 ML	1,000
236	236	Budesonide 100 mcg/dose	30 Rotacaps	21,000	As per standard packing	10,000
237	237	Budesonide 200 mcg	30 Rotacaps	21,000	As per standard packing	10,000
238	238	Budesonide 200 mcg/dose Inhaler	200 md	21,000	As per standard packing	10,000
239	239	Cetirizine (5 mg/ 5 ml) Syrup	60 ml bottles	52,500	50X60 ML	7,000
240	240	Cetirizine 10mg film coated Tablets	10x10	105,000	100 X 10X10's	44,000
241	241	Cough Syrup (Dextromethorphan Based) Syrup	100 ml bottles	52,500	50X100 ML	16,000
242	242	Cough Syrup CPM 3 mg. + A.Chl.110 mg. +Sod. Cit.46 mg. + Menthol IP 0.9 mg (Deacos)	110ml bottles	105,000	50X110 ML	21,000
243	243	Cough Syrup Diphen.14 mg. + A.Chl.135 mg. + Sod.Cit.57 mg. + Menthol IP 0.9 mg.	110ml bottles	105,000	100X110 ML	23,000
244	244	Etophyllin + Theophylline (84.7 mg + 25.3 mg) Ini.	2 ml	31,500	50X10X2 ML	3,000
245	245	Etophyllin +Theophylline (77 mg + 23 mg) Tabs	10x10	10,500	100 X 10X10's	7,000
246	246	Fexofenadine 120 mg film coated Tablets	10x10	10,500	100 X 10X10's	2,000
247	247	Fexofenadine 180 mg film coated Tablets	10x10	10,500	100 X 10X10's	2,000
248	248	Levocetirizine 5 mg film coated Tablets	10x10	105,000	100 X 10X10's	94,000
249	249	Levocetirizine HCl + Pseudoephedrine + Paracetamol (5 mg + 20 mg + 500mg) Tabs	10x10	31,500	100 X 10X10's	48,000
250	250	Montelukast Sodium 5 mg Tab	10x10	31,500	100 X 10X10's	31,000
251	251	Montelukast Sodium 10 mg Tab	10x10	52,500	100 X 10X10's	105,000
252	252	Montelukast Sodium + Levocetirizine (10 mg + 5mg) film coated Tablets	10x10	52,500	100 X 10X10's	120,000
253	253	Pheniramine Maleate 25 mg Tabs	10x10	10,500	100 X 10X10's	2,000
254	254	Promethazine (5 mg/ 5ml) Syrup	100ml bottles	52,500	50X100 ML	9,000
255	255	Salbutamol 100 mcg/puff Inhaler	200 md	31,500	30X200 MD	15,000

256	256	Salbutamol 2 mg Tabs	10x10	10,500	100 X 10X10's	1,000
257	257	Salbutamol 2.5 mg Respule	2.5 ml	31,500	As per standard packing	1,000
258	258	Salbutamol 200 mcg	30 Rotacaps	21,000	As per standard packing	-
259	259	Salbutamol 2mg /5ml Syrup	100 ml bottles	21,000	100X100 ML	2,000
260	260	Salbutamol 4 mg Tabs	10x10	21,000	100 X 10X10's	6,000
<b>CARDIOVASCULAR DRUGS/ DIURETICS/HYPOLIPIDAEMIC</b>				-		-
261	261	Adenosine 6 mg/ 2ml Amp.	2 ml	21,000	50x10x 2ml	-
262	262	Amiodarone 100 mg Tabs	10x10	10,500	100 X 10X10's	5,000
263	263	Amlodipine + Atenolol (5 mg + 50 mg) film coated Tablets	10x10	105,000	100 X 10X10's	90,000
264	264	Amlodipine 5mg film coated Tablets	10x10	52,500	100 X 10X10's	30,000
265	265	Atenolol 50 mg Tabs	14x10	105,000	100x14x10 's	113,000
266	266	Atorvastatin 10mg film coated Tablets	10x10	105,000	100 X 10X10's	133,000
267	267	Atorvastatin 20 mg film coated Tablets+C297	10x10	52,500	100 X 10X10's	89,000
268	268	Clonidine 0.1 mg Tabs	10x10	10,500	100 X 10X10's	2,000
269	269	Clopidogrel 75mg Tabs	10x10	105,000	100 X 10X10's	186,000
270	270	Clopidogrel 75mg Tabs + Aspirin 75 mg	10x10	105,000	100 X 10X10's	23,000
271	271	Diltiazem 30 mg Tabs	10x10	52,500	100 X 10X10's	15,000
272	272	Diltiazem 60 mg Tabs	10x10	21,000	100 X 10X10's	7,000
273	273	Dobutamine 250 mg/ 20ml Inj.	Vial	10,500	10x10x20 ml	-
274	274	Dopamine HCl 200 mg/5ml Inj.	5 ml	21,000	10x10x5 ml	1,000
275	275	Enalapril 5mg Tabs	10x10	21,000	100 X 10X10's	21,000
276	276	Enoxaparin 40 mg/0.4 ml Inj.	0.4 ml	21,000	As per standard packing	2,000
277	277	Enoxaparin 60 mg/0.6 ml Inj.	0.6 ml	21,000	As per standard packing	2,000
278	278	Frusemide (10 mg/ ml)	2ml	21,000	100x10x2ml	-
279	279	Frusemide 40 mg Tabs	10x10	105,000	100 X 10X10's	45,000
280	280	Heparin Sodium 1000iu/ ml Inj.	5 ml	52,500	20x10x5ml	57,000
281	281	Heparin Sodium 5000iu/ ml Inj.	5 ml	105,000	20x10x5ml	115,000

282	282	Hydrochlorothiazide 12.5 mg Tabs	10x10	52,500	100 X 10X10's	12,000
283	283	Isosorbide Dinitrate 10 mg Tabs	10x10	52,500	100 X 10X10's	12,000
284	284	Isosorbide Mononitrate 10 mg Tabs	10x10	52,500	100 X 10X10's	60,000
285	285	Lisinopril + Amlodipine (5 mg + 5mg) Tabs	10x10	52,500	100 X 10X10's	96,000
286	286	Lisinopril 5mg Tabs	10x10	52,500	100 X 10X10's	71,000
287	287	Losartan + H.Ch. Thiazide (50 mg + 12.5mg) film coated Tablets	10x10	52,500	100 X 10X10's	125,000
288	288	Losartan 25mg film coated Tablets	10x10	52,500	100 X 10X10's	54,000
289	289	Losartan Potassium 50 mg film coated Tablets	10x10	105,000	100 X 10X10's	152,000
290	290	Metoprolol 25 mg Tabs	10x10	10,500	100 X 10X10's	15,000
291	291	Metoprolol 50 mg Tabs	10x10	10,500	100 X 10X10's	20,000
292	292	Nifedipine 10 mg Caps	10x10	10,500	100 X 10X10's	11,000
293	293	Ramipril 2.5 mg Tabs	10x10	10,500	100 X 10X10's	10,000
294	294	Ramipril 5 mg Tabs	10x10	52,500	100 X 10X10's	73,000
295	295	Simvastatin 10 mg Tabs	10x10	10,500	100 X 10X10's	10,000
296	296	Simvastatin 20 mg Tabs	10x10	21,000	100 X 10X10's	31,000
297	297	Tamsulosin Hydrochloride 0.4 mg Caps	10x10	21,000	100 X 10X10's	-
298	298	Telmisartan + Hydrochlorthiazide (40 mg + 12.5 mg ) Tabs	10x10	31,500	100 X 10X10's	53,000
299	299	Telmisartan 20 mg Tabs	10x10	21,000	100 X 10X10's	27,000
300	300	Telmisartan 40 mg Tabs	10x10	21,000	100 X 10X10's	31,000
301	301	Tranexamic Acid 500 mg Tabs	10x10	10,500	100 X 10X10's	2,000
302	302	Tranexamic Acid 500 mg/5ml Inj.	5 ml Amp.	10,500	As per standard packing	1,000
<b>ANTIMALARIAL DRUGS</b>				-		-
303	303	Artesunate 50mg Tabs	10x10	10,500	100 X 10X10's	19,000
304	304	Arteether 150mg inj	2ml Vial	10,500	As per standard packing	1,000
305	305	Chloroquine Phosphate 250 mg film coated Tablets	10x10	21,000	100 X 10X10's	13,000
306	306	Primaquine 15 mg film coated Tablets	10x10	10,500	100 X 10X10's	56,000
307	307	Primaquine 2.5 mg film coated Tablets	10x10	10,500	100 X 10X10's	32,000



308	308	Primaquine 5 mg film coated Tablets	10x10	10,500	100 X 10X10's	37,000
309	309	Sulphadoxine + Pyrimethamine 250 mg + 12.5 mg/5ml Syrup	10 ml bottles	21,000	50x10x10ml	4,000
310	310	Sulphadoxine + Pyrimethamine 500 mg + 25 mg Tabs	(2X5X10)	10,500	100X 2X5X10	3,000
<b>ELECTROLYTES</b>				-		-
311	311	Disodium hydrogen Citrate (Alkalyser) 1.4 mg/5ml Syrup	100 ml bottles	105,000	100X100 ML	35,000
312	312	Oral Rehydration Salts Citrate IP 21 GM (WHO Formula) Sachet	1S	210,000	30x10x21.5 gm	13,000
<b>CNS DRUGS/ANTI-EPILEPTIC DRUGS</b>				-		-
313	313	Alprazolam 0.25 mg film coated Tablets	10x10	21,000	100 X 10X10's	8,000
314	314	Alprazolam 0.5 mg film coated Tablets	10x10	52,500	100 X 10X10's	24,000
315	315	Betahistine 16 mg Tabs	10x10	10,500	100 X 10X10's	2,000
316	316	Betahistine 8 mg Tabs	10x10	10,500	100 X 10X10's	2,000
317	317	Carbamazepine 100mg Tabs	10x10	10,500	100 X 10X10's	7,000
318	318	Carbamazepine 200mg Tabs	10x10	21,000	100 X 10X10's	29,000
319	319	Clonazepam 0.5 mg Tabs	10x10	10,500	100 X 10X10's	5,000
320	320	Diazepam 5 mg Tabs	10x10	21,000	100 X 10X10's	7,000
321	321	Escitalopram 10 mg Tabs	10x10	10,500	100 X 10X10's	-
322	322	Escitalopram 20 mg Tabs	10x10	10,500	100 X 10X10's	-
323	323	Flunarzine 10mg Tabs	10x10	31,500	100 X 10X10's	70,000
324	324	Flunarzine 5mg Tabs	10x10	21,000	100 X 10X10's	24,000
325	325	Fluoxetine hydrochloride 20 mg Caps	10x10	10,500	100 X 10X10's	-
326	326	Methyl Ergometrine 0.125mg Tabs	10x10	10,500	100 X 10X10's	11,000
327	327	Phenytoin Sodium 100 mg Tabs	10x10	21,000	100 X 10X10's	46,000
328	328	Prochlorperazine 5 mg Tabs	10x10	21,000	100 X 10X10's	4,000
<b>CORTICO – STEROIDS/DRUG USED IN HYPOTHYROIDISM</b>				-		-
329	329	Prednisolone 5 mg Tabs	10x10	21,000	100 X 10X10's	2,000
330	330	Prednisolone 10 mg Tabs	10x10	31,500	100 X 10X10's	5,000
331	331	Thyroxine Sodium 50 mcg Tabs	10x10	21,000	100 X 10X10's	4,000

332	332	Thyroxine Sodium 100 mcg Tabs	10x10	21,000	100 X 10X10's	9,000
333	333	Dexamethasone 0.5 mg Tabs	10x10	21,000	100 X 10X10's	20,000
334	334	Dexamethasone 40 mg Inj.	2 ml	105,000	50x10x2 ml	10,000
<b>DIETARY SUPPLEMENT</b>				-		-
335	335	Protein Powder	200 g Jar	105,000	30x200 gms	69,000
<b>DRUGS USED IN GOUT</b>				-		-
336	336	Allopurinol 100 mg Tabs	10x10	10,500	100 X 10X10's	4,000
<b>HORMONES AND RELATED DRUGS</b>				-		-
337	337	Clomiphene citrate 50 mg Tabs	10x10	10,500	100 X 10X10's	4,000
<b>OPHTHALMIC PREPARATION</b>				-		-
338	338	Atropine Sulphate (0.6mg/ ml) Inj.	1ml	52,500	100x10x1ml	1,000
339	339	Betaxolol Hydrochloride 0.5 % w/w Eye Drop	5 ml	52,500	30x10x5ml	8,000
340	340	Acyclovir 3% w/w Eye Onit.	5 g	105,000	30x10x5gm	23,000
341	341	Carboxymethyl Cellulose 0.5 % w/v Eye Drop	10 ml	31,500	20x10x10 ml	5,000
342	342	Chloramphenicol 1 % w/v Eye Drop	5 ml	52,500	30x10x5ml	5,000
343	343	Chloramphenicol 1 % w/v Eye Applicaps	100 Applicaps	105,000	As per standard packing	25,000
344	344	Ciprofloxacin 0.3% w/v Eye Drop	5 ml	315,000	30x10x5ml	31,000
345	345	Gentamycin 0.3% w/v Eye Drop	5 ml	105,000	30x10x5ml	10,000
346	346	Ketorolac Tromethamine 0.5 % w/v Eye Drop	5 ml	52,500	30x10x5ml	9,000
347	347	Prednisolone Acetate 1 % w/v Eye Drop	5 ml	52,500	30x10x5ml	5,000
348	348	Sulphacetamide Sodium 10 % w/v Eye Drop	10 ml	105,000	20x10x10 ml	16,000
349	349	Sulphacetamide Sodium 20 % w/v Eye Drop	10 ml	105,000	20x10x10 ml	16,000
350	350	Timolol Maleate 0.5 % w/v Eye Drop	5 ml	52,500	30x10x5ml	9,000
<b>OROPHARYNGEAL</b>				-		-
351	351	Xylometazoline 0.1 % w/v Nasal Drop	10 ml	105,000	20x10x10 ml	16,000
<b>SURGICAL ANESTHETICS</b>				-		-
352	352	Bupivacaine Hydrochloride 0.5% w/w Inj.	4 ml X 5	21,000	As per standard packing	4,000

353	353	Ketamine Hydrochloride 10 mg/ml Inj.	10 ml	21,000	20x10x10 ml	4,000
354	354	Ketamine Hydrochloride 50 mg/ml Inj.	2 ml	21,000	50x10x2ml	6,000
355	355	Lignocaine 1% w/v Inj.	20 ml Vial	31,500	10x10x20 ml	3,000
356	356	Lignocaine 2% w/v Inj.	20 ml Vial	31,500	10x10x20 ml	3,000
357	357	Lignocaine + Adrenaline (1% + 2%)w/v Inj.	30 ml Vial	31,500	10x10x30ml	6,000
358	358	Propofol 10 mg/ml Inj.	10ml Vial	21,000	20x10x10 ml	4,000
<b>VACCINES</b>				-		-
359	359	Tetanus Toxoid Inj.	0.5 ml Amp.	1,050,000	As per standard packing	42,000
<b>OTHERS</b>				-		-
360	360	Mifepristone 200 mg Tabs	1x10	10,500	As per standard packing	4,000
361	361	Oxytocin 5 iu / ml Inj.	1 ml Amp.	52,500	50x10x1ml	5,000

**I. SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES**  
**GENERAL SPECIFICATIONS**

1. No corrugate package should weigh more than 15 kgs (ie., product + inner carton + corrugated box).
2. All Corrugated boxes should be of 'A' grade paper ie., Virgin.
3. All items should be packed only in first hand boxes only.

**FLUTE:**

4. The corrugated boxes should be of narrow flute.

**JOINT:**

5. Every box should be preferably single joint and not more than two joints.

**STITCHING:**

6. Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.

**FLAP:**

7. The flaps should uniformly meet but should not overlap each other. The flap when turned by 45 - 60° should not crack.

**TAPE:**

8. Every box should be sealed with gum tape running along the top and lower opening.

**CARRYSTRAP:**

9. Every box should be strapped with two parallel nylon carry straps (they should intersect).

**LABEL:**

10. The product label on the carton should be large atleast 15cms x 10cms dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.

**OTHERS:**

12. No box should contain mixed products or mixed batches of the same product.

**II. SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS / CAPSULES / PESSARIES**

- (1) The box should not weigh more than 7-8 kgs. The grammage of outer box should be 150 gsm and inside partition / lining should be 120gsm.
- (2) The box should be of 5 ply with Bursting strength of 9 Kg/ Cm<sup>2</sup>

**III. SPECIFICATIONS FOR OINTMENT / CREAM / GELS PACKED IN TUBES:**

- (1) No corrugate box should weigh more than 7-8 Kgs.
- (2) Every Ointment tube should be individually packed in carton and then

packed in 20's in a grey board box, which may be packed in a corrugated box.

- (3) Grammage : Outer box should be 150 gsm  
inside partition / lining should be 120gsm.

## **VII. SPECIFICATIONS FOR INJECTABLE (IN VIALS AND AMPOULES)**

- (1) Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 kgs.
- (2) C.B. for vials should be of 150 Gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply, while C.B. for ampoules should be of 150 Gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 5 ply.
- (3) Bursting strength for CB boxes for
- a. Vials : Note less than 13 Kg/Cm<sup>2</sup>
  - b. Amp : Note less than 9 Kg/Cm<sup>2</sup>
- (4) In the case of 10 ml Ampoules 100 or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.
- (5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with centre pad.
- (6) In case of ampoules every grey board box should carry 5 amps. Cutters placed in a polythene bag.
- (7) Vials of eye and ear drops should be packed in an individual carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

**AGREEMENT**

THIS AGREEMENT made the..... day of ....., 2013 Between Bureau of Pharma Public Sector Undertakings of India, IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

(Name of purchaser) of ..... (Country of Purchaser) (here in after "the Purchaser") of the one part and ..... (Name of Supplier) of ..... (City and Country of Supplier) (here in after called "the Supplier") of the other part :

WHEREAS the Purchaser is desirous that certain Goods and ancillary services viz;. Supply of Drugs and Medicines in the tender Reference No. BPPI/DRUGS/001 (Brief Description of Goods and Services) and has accepted a bid by the Supplier for the supply of those goods and services for the sum of .....(Contract Price in Words and Figures) (hereinafter called "the Contract Price").

**NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:**

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to, and they shall be deemed to form and be read and construed as part of this agreement.

2. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz.:

- (a) The Letter of Acceptance issued by the purchaser.
- (b) The Notice Inviting Tender
- (c) The supplier's bid including enclosures, annexures, etc.
- (d) The Terms and Conditions of the Contract
- (e) The Schedule of Requirement
- (f) The Technical Specification

- (g) Any other document listed in the supplier's bid and replies to queries, clarifications issued by the purchaser, such confirmations given by the bidder which are acceptable to the purchaser and the entire Addendum issued as forming part of the contract.

3. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide, the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract.

4. The purchaser hereby covenants to pay the Supplier in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

Brief particulars of the goods and services which shall be supplied / provided

by the Supplier are as under.

Sl. No	Drug Code	Brief Description of Goods & Services	Tender Qty in Unit*	Unit Price	Sales tax in %	Total value inclusive of sales tax
Total contract value						

\* Tender quantity indicated here is tentative and may vary subjected to various terms and conditions of the tender.



**DELIVERY SCHEDULE:**

Supply shall commence within 30/45 days and shall complete within 60 days from the date of purchase order.

IN WITNESS where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered by the

said..... (For the Purchaser)

in the presence of .....

Signature

Name

Address

Signed, Sealed and Delivered by the

Said ..... (For the Supplier)

in the presence of .....

Signature

Name

Address

**Performance Security Bank Guarantee**

(unconditional)

To : Bureau of Pharma Public Sector Undertakings of India, (Name of purchaser) IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

**WHEREAS** ..... (Name of the Supplier) herein called “the Supplier” has undertaken, in pursuance of Tender BPPI/DRUGS/001 to supply of **Drugs and Medicines for the year 2013-2015**. (Description of Goods and Services) hereinafter called “the Contract”.

**AND WHEREAS** it has been stipulated by you in the said Contract that the Supplier shall furnish you with a Bank Guarantee by a recognised bank for the sum specified therein as security for compliance with the Supplier’s performance obligations in accordance with the Contract.

**AND WHEREAS** we have agreed to give the Supplier a Guarantee

**THEREFORE WE** hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, upto a total of ..... (Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the Contract and without cavil or argument,

any sum or sums within the limit of ..... (Amount of the Guarantee  
in Words and Figures) as aforesaid, without your needing to prove or to show  
grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until the ..... day of ..... 20....

Signature and Seal of Guarantors

.....

.....

.....

Date ..... 20 .....

Address .....

.....

.....

**DETAILS OF MANUFACTURING/IMPORTING UNIT**

Name of the Tenderer & Full Address :

PAN Number :

TIN Number :

Phone Nos. :

Fax :

E-Mail :

Date of Inception

Licence No. & Date :

Issued by :

Valid up to :

Details of installed Production Capacity :

**Detailsof Installed Production Capacityfor 1year**  
**(In Terms of Unit Packs)**

Tablets :

**Capsules**

General :

Beta-Lactum :

**Injections**

Ampoules :

Vials :

I.V.Fluids :

Sterile Powder :

**Liquids**

Suspension :

Syrups :

Drops :

Ointment :

Powders :

Antiseptics /  
Disinfectants :

Name & designation of the authorised signatory :

Specimen signature of the authorized Signatory :

\* The details of manufacturing unit shall be for the premises where items quoted are actually manufactured

**ANNEXURE – XIV****Ref. clause 4.1 (r)****List of items quoted**

1. Name of the firm and address  
as given in Drug licence :
2. Drug Licence No. in form 25 & 28  
or import Licence No. :
3. Date of issue & validity :
4. Revised schedule M compliance  
Certificate obtained on :
5. Non-conviction Certificate  
Obtained on :
6. Market standing Certificate  
obtained on :
7. Annual Production Capacity earmarked to  
BPPI :

In the event of the bidder becoming L1 for more than one item, if the total annual quantity for such items is more than the capacity earmarked to BPPI, BPPI reserve the rights to decide any appropriate item(s) within his production capacity.

8. Details of Endorsement for all products quoted :

Sl. No	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name	Qty Earmarked for BPPI	Mfg Capacity for BPPI (1 year)	Value of EMD
1.								
EMD Total								

**Authorised signatory :****Date :**

**MANDATE FORM**

<b>01</b>	<b>Company Name</b>	
<b>02</b>	<b>Postal Address of the company with Telephone No., Fax No. and Mail I.D.</b>	
<b>03</b>	<b>Name of the Managing Director / Director / Manager  Mobile No. / Phone No.  E-mail I.D.</b>	
<b>04</b>	<b>Name and Designation of the authorized company official  Mobile No.  E-mail ID</b>	

Date:                      Company Seal

Signature

Place:    (Name of the person signing & designation)

<b>01</b>	<b>Name of the Bank .</b>  <b>Branch Name&amp; address.</b>  <b>Branch Code No.</b>  <b>Branch Manager Mobile No.</b>  <b>Branch Telephone no.</b>  <b>Branch E-mail ID</b>	
<b>02</b>	<b>9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank.</b>	
<b>03</b>	<b>IFSC code of the Branch</b>	
<b>04</b>	<b>Type of Account (Current / Savings).</b>	
<b>05</b>	<b>Account Number (as appear in cheque book)</b>	

(in lieu of the bank certificate to be obtained , please **attach the original cancelled cheque** issued by your bank for verification of the above particulars).

I /We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information, I would not hold Bureau of Public Sector Undertakings of India (BPPI) responsible. I have read the conditions



of the tender/agreement entered and agree to discharge the responsibility expected of me / from the company as a tenderer /successful tenderer.

Date:

Company Seal

Signature

Place:

(Name of the person signing & designation)

-----

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Bank Seal with address.

Signature of the authorized  
official of the bank.

-----

**CHECKLIST**

**ANNEXURE - XVII**  
**Ref. Clause. 4.1.(s)**

**COVER - A.**

1. Checklist – Annexure-XVII	<div>1</div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>
2. EMD in the form of DD shall be kept in an envelop as per Annexure-V. SSI certificate for exemption	<div></div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>
3. Under taking of domestic SSI units in form Annexure-VI	<div></div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>
4. Documentary evidence for the constitutions of the company / concern	<div></div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>
5. Duly attested photocopy of Licence for the product duly approved by the Licencing authority for each and every product quoted.	<div></div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>
6. Duly attested photocopy of Import Licence, if imported and whole sale Drug licence	<div></div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>
7. The instruments such as power of attorney, resolution of board etc.,	<div></div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>
8. Authorization letter nominating a responsible person of the tenderer to transact the business with the Tender inviting Authority.	<div></div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>
9. Market Standing Certificate issued by the Licensing Authority	<div></div>	<div>Yes</div>	<div></div>	<div>No</div>	<div></div>

10. True copy of record of manufacture to establish 3 years market standing.	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
11. Non Conviction Certificate issued by the Drugs Controller	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
12. Good Manufacturing Practices Certificate	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
13. Annual Turnover Statement for 3 Years (Annexure-VIII)	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
14. Copies of balance sheet & profit loss account for three years	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
15. Annexure-I (Sales Tax clearance certificate)	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
16. Annexure-II (Undertaking for embossment of logo)	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
17. Annexure-II (A) (Undertaking for embossment of logo)	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
18. Declaration Form in Annexure-III along with enclosure.	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
19. Proforma for Performance Statement (Annexure-VII)	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>
20. Details of Manufacturing/Importing Unit in Annexure-XIII	<input type="checkbox"/>	Yes <input type="checkbox"/>	No <input type="checkbox"/>

21. WHO certificates if any		Yes		No	
22. Details of Technical personnel employed in the manufacture and testing		Yes		No	
23. List of items quoted without rates. Annexure-XIV		Yes		No	
24. Mandate Form Annexure-XVI		Yes		No	
25. The Tender document signed by the tenderer in all pages with office seal.		Yes		No	

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
<b>ANALGESIC/ ANTI-INFLAMMATORY/ MUSCLOSKELETAL DISORDER</b>								
1	1	Aceclofenac + Paracetamol (100 mg + 500mg) Tablets	10x10	52,500				
2	2	Aceclofenac 100 mg Tablets	10x10	21,000				
3	3	Aceclofenac Gel	30 g tubes	105,000				
4	4	Acetaminophen + Tramadol Hydrochloride (325 mg + 37.5 mg) film coated Tablets	10x10	21,000				
5	5	Asprin 150 mg Tab	14x10	52,500				
6	6	Chlorzoxazone + Diclofenac + Paracetamol (500 mg + 50 mg + 500 mg)	10x10	21,000				
7	7	Diclofenac Gel	15 g	210,000				
8	8	Diclofenac Sodium + Serratiopeptidase (50mg + 10mg) Tab	10x10	21,000				
9	9	Diclofenac Sodium (SR) 100 mg Tab	10x10	105,000				
10	10	Diclofenac Sodium 25mg per ml Inj.	3 ml	105,000				
11	11	Diclofenac Sodium 50 mg Tab	10x10	105,000				
12	12	Etoricoxib 120mg Tab	10x10	21,000				
13	13	Etoricoxib 90mg Tab	10x10	21,000				
14	14	Ibuprofen + Paracetamol (400 mg + 325 mg) Tab	10x10	105,000				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPT (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	In words
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
15	15	Ibuprofen 200mg film coated Tablets	10x10	21,000				
16	16	Ibuprofen 400 mg film coated Tablets	10x10	52,500				
17	17	Indomethacin 25 mg Cap	10x10	10,500				
18	18	Methyl Salicylate Oint.(Eutheria)	20 g	105,000				
19	19	Nimesulide + Paracetamol (100 mg + 500mg) Tab	10x10	105,000				
20	20	Nimesulide 100 mg Tab	10x10	52,500				
21	21	Paracetamol + Diclofenac Sodium (500 mg + 50 mg) Tab	10x10	105,000				
22	22	Paracetamol 125 mg / 5 ml Syrup	60 ml bottles	105,000				
23	23	Paracetamol 500mg Tab	10x10	210,000				
24	24	Pentazocine 30 mg/ ml Inj.	1 ml	52,500				
25	25	Serratiopeptidase 10 mg Tab	10x10	10,500				
26	26	Tramadol 100 mg Inj.	2ml	105,000				
27	27	Tramadol 50 mg Inj.	1ml	52,500				
28	28	Tramadol 50 mg Tab	10x10	21,000				
<b>ANTIBIOTICS</b>				-				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII			Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPT (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)			Total Value (5X7) in figures
						In figures		In words	
						RS.	Paise		
(1)	(2)	(3)	(4)	(5)	(6)	(7)			(8)
29	29	Acyclovir 400 mg film coated Tablets	10x10	21,000					
30	30	Amikacin 100mg inj.	Vial	105,000					
31	31	Amikacin 250mg inj.	Vial	52,500					
32	32	Amikacin 500mg inj.	Vial	157,500					
33	33	Amoxycillin + Bromhexine (250 mg + 8 mg) Caps	10x10	52,500					
34	34	Amoxycillin + Bromhexine (500 mg + 8 mg) Caps	10x10	52,500					
35	35	Amoxycillin + Clavulanic acid (1000 mg + 200mg) Ini.	Vial	105,000					
36	36	Amoxycillin + Clavulanic acid (200 mg+28.5 mg /5ml) Dry Syrup	30 ml bottles	157,500					
37	37	Amoxycillin + Clavulanic acid (250 mg + 50 mg) Ini.	Vial	52,500					
38	38	Amoxycillin + Clavulanic acid (500 mg + 100mg) Ini.	Vial	52,500					
39	39	Amoxycillin + Clavulanic acid (500 mg + 125 mg) film coated Tablets	6x10	52,500					
40	40	Amoxycillin + Cloxacillin (250 mg + 250 mg) Caps	10x10	52,500					
41	41	Amoxycillin + Di-Cloxacillin (250 mg + 250 mg) Caps	10x10	21,000					
42	42	Amoxycillin 125 mg Kid Tabs	10x10	52,500					
43	43	Amoxycillin 125mg/ 5ml Dry Syrup	60 ml bottles	105,000					

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII			Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)			Total Value (5X7) in figures
						In figures		In words	
						RS.	Paise		
(1)	(2)	(3)	(4)	(5)	(6)	(7)			(8)
44	44	Amoxycillin 250 mg Caps	10x10	21,000					
45	45	Amoxycillin 500 mg Caps	10x10	52,500					
46	46	Ampicillin 500mg inj.	Vial	21,000					
47	47	Azithromycin (100mg/ 5ml) Syrup	15 ml bottles	105,000					
48	48	Azithromycin 100 mg DT Tab	10x10	52,500					
49	49	Azithromycin 250 mg film coated Tablets	10x10	52,500					
50	50	Azithromycin 500 mg film coated Tablets	10x10	105,000					
51	51	Cefadroxil 250 mg film coated Tablets	10x10	21,000					
52	52	Cefadroxil 500 mg film coated Tablets	10x10	52,500					
53	53	Cefixime (50 mg/ 5ml) Dry Syrup	30 ml bottles	105,000					
54	54	Cefixime 100mg film coated Tablets	10x10	52,500					
55	55	Cefixime 200mg film coated Tablets	10x10	105,000					
56	56	Cefoperazone + Sulbactam ( 1g + 1g) Inj.	vial	52,500					
57	57	Cefoperazone + Sulbactam (500 mg + 500 mg) Ini.	vial	105,000					
58	58	Cefoperazone 1 gm Inj.	Vial	52,500					

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPT (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
59	59	Cefotaxime Sodium & Sulbactam Sodium (1g + 500 mg) Inj.	Vial	52,500				
60	60	Cefotaxime Sodium & Sulbactam Sodium (250 mg + 125 mg) Inj.	Vial	21,000				
61	61	Cefotaxime Sodium & Sulbactam Sodium (500 mg + 250 mg) Inj.	Vial	21,000				
62	62	Cefotaxime Sodium 1000mg Inj.	Vial	105,000				
63	63	Cefotaxime Sodium 250 mg Inj.	Vial	21,000				
64	64	Cefotaxime Sodium 500 mg Inj.	Vial	21,000				
65	65	Cefpodoxime 100 mg DT	10x10	52,500				
66	66	Cefpodoxime 200 mg film coated Tablets	10x10	105,000				
67	67	Ceftazadime 1000 mg Inj.	Vial	21,000				
68	68	Ceftazadime 250 mg Inj.	Vial	21,000				
69	69	Ceftazadime 500 mg Inj.	Vial	52,500				
70	70	Ceftriaxone + Sulbactam (1000 mg + 500 mg) Inj.	Vial	52,500				
71	71	Ceftriaxone + Tazobactam 1000 mg + 125 mg Inj.	Vial & wfi	21,000				
72	72	Ceftriaxone + Tazobactam 250 mg + 31.25 mg Inj.	Vial & wfi	21,000				
73	73	Ceftriaxone +Sulbactam (250 mg + 125 mg)	Vial	52,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPT (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
74	74	Ceftriaxone +Sulbactam (500 mg + 250 mg)	Vial	52,500				
75	75	Ceftriaxone 1 g Inj.	Vial	157,500				
76	76	Ceftriaxone 250 mg Inj.	Vial	52,500				
77	77	Ceftriaxone 500 mg Inj.	Vial	52,500				
78	78	Cefuroxime Axetil 250 mg film coated Tablets	10x10	52,500				
79	79	Cefuroxime Axetil 500mg film coated Tablets	10x10	21,000				
80	80	Cephalexin 125 mg DT	10x10	52,500				
81	81	Cephalexin 250 mg Caps	10x10	21,000				
82	82	Cephalexin 500 mg Caps	10x10	52,500				
83	83	Ciprofloxacin + Tinidazole (250 mg + 300 mg) film coated Tablets	10x10	21,000				
84	84	Ciprofloxacin + Tinidazole (500 mg + 600 mg) film coated Tablets	10x10	52,500				
85	85	Ciprofloxacin 250 mg film coated Tablets	10x10	21,000				
86	86	Ciprofloxacin 500 mg film coated Tablets	10x10	157,500				
87	87	Clotrimazole 1% w/w 0int.	15 g tubes	105,000				
88	88	Co-trimoxazole (Sulphamethoxazole 200mg + Trimethoprim 40mg / 5ml) Susp	50 ml bottle	105,000				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
89	89	Co-trimoxazole -DS (160 mg + 800 mg) Tabs	10x10	105,000				
90	90	Co-trimoxazole- Pead. (20 mg + 100 mg) Tabs	10x10	21,000				
91	91	Co-trimoxazole –SS (80 mg + 400 mg)	10x10	52,500				
92	92	Doxycycline 100 mg Caps	10x10	52,500				
93	93	Erythromycin Stearate 250 mg film coated Tablets	10x10	52,500				
94	94	Gentamycin Sulphate 80 mg/ 2ml Inj.	2 ml	21,000				
95	95	Levofloxacin 250 mg film coated Tablets	10x10	21,000				
96	96	Levofloxacin 500 mg film coated Tablets	10x10	21,000				
97	97	Meropenem 1gm Inj.	Vial	52,500				
98	98	Norfloxacin + Tinidazole (400 mg + 600 mg) film coated Tablets	10x10	10,500				
99	99	Norfloxacin 400 mg film coated Tablets	10x10	10,500				
100	100	Ofloxacin + Ornidazole (200 mg + 500 mg) film coated Tablets	10x10	21,000				
101	101	Ofloxacin 200 mg film coated Tablets	10x10	21,000				
102	102	Ofloxacin 400 mg film coated Tablets	10x10	52,500				
103	103	Piperacillin + Tazobactam 4 g + 0.5 mg Inj.	Vial & wfi	52,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
104	104	Roxithromycin (50 mg/ 5ml) Susp.	30 ml bottles	21,000				
105	105	Roxithromycin 150 mg film coated Tablets	10x10	21,000				
106	106	Roxithromycin 300 mg film coated Tablets	10x10	10,500				
107	107	Tinidazole 300 mg film coated Tablets	10x10	10,500				
108	108	Tinidazole 500 mg film coated Tablets	10x10	10,500				
109	109	Vancomycin 500 mg	Vial	21,000				
<b>ANTI INFECTIVES (TOPICALS)/ ANTIFUNGAL/ SKIN OINTMENT</b>				-				
110	110	Adapalene 0.1 % w/v Ointment	15 g tubes	21,000				
111	111	Application Benzyl Benzoate 25 % w/w Lotion	100 ml	52,500				
112	112	Beclomethasone + Clotrimazole + Gentamycin (0.025%+1.0%+0.1% w/w)	15 g tubes	52,500				
113	113	Beclomethasone + Neomycin (0.025% + 0.5% w/w) Cream	15 g tubes	52,500				
114	114	Beclomethasone Dipropionate 0.025% w/v Oint.	15 g tubes	21,000				
115	115	Calamine Lotion	100 ml bottles	31,500				
116	116	Chlorhexidine Gluconate 5% Solution	500 ml bottles	21,000				
117	117	Chlorhexidine Gluconate 0.2% Mouth Wash	150 ml bottles	31,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
118	118	Clobetasol Propionate 0.05 % w/w Cream	15 g tubes	31,500				
119	119	Fluconazole 150 mg film coated Tablets+C158+C158	10x10	42,000				
120	120	Fusidic Acid 2 % w/v Cream	10 g tubes	21,000				
121	121	Glutaraldehyde 2% w/v Solution	500 ml bottles	31,500				
122	122	Ketoconazole 2 % w/w Lotion	100 ml bottles	31,500				
123	123	Lignocaine 2% w/w Ointment	30 g tubes	31,500				
124	124	Povidone Iodine 5% w/w Ointment	250 gm tubes	21,000				
125	125	Povidone Iodine 5%w/w Ointment	15 gm tubes	157,500				
126	126	Povidone Iodine 10 % Solution	500 ml bottles	21,000				
127	127	Povidone Iodine 5 % Solution	100 ml bottles	31,500				
128	128	Povidone Iodine 5 % Solution	500 ml bottles	21,000				
129	129	Povidone Iodine 7.5% Solution	500 ml bottles	10,500				
130	130	Ravlon Solution (Chlorhexidine + Cetramide ) (1.5 % w/v + 3% w/v)	100 ml bottles	21,000				
131	131	Silver Sulphadiazine 1 % w/w Cream	20 gm tubes	105,000				
132	132	Silver Sulphadiazine 1 % w/w Cream	500 gm jars	21,000				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII			Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPT (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)			Total Value (5X7) in figures
						In figures		In words	
						RS.	Paise		
(1)	(2)	(3)	(4)	(5)	(6)	(7)			(8)
		ANTIDIABETIC DRUGS		-					
133	133	Glibenclamide 2.5 mg Tabs (Scored Oval)	10x10	21,000					
134	134	Glibenclamide 5 mg Tabs (Scored Oval)	10x10	21,000					
135	135	Gliclazide 40 mg Tabs	10x10	21,000					
136	136	Gliclazide 80 mg Tabs	10x10	21,000					
137	137	Glimeperide 1mg Tab	10x10	105,000					
138	138	Glimeperide 2mg Tabs	10x10	105,000					
139	139	Glimeperide 1mg + Metformin 500mg + Pioglitazone 15mg	10x10	21,000					
140	140	Glimeperide 2mg + Metformin 500mg + Pioglitazone 15mg	10x10	21,000					
141	141	Glipizide 5 mg Tabs	10x10	21,000					
142	142	Insulin Injection (Human) (40iu/ml)	10 ml Vial	42,000					
143	143	Insulin Injection {Insulin Human (Soluble 30% & Isophane 70%) 40iu/ml}	10 ml Vial	21,000					
144	144	Metformin Hydrochloride 1000 mg SR Tabs	10x10	31,500					
145	145	Metformin Hydrochloride 500mg Tabs	10x10	210,000					
146	146	Pioglitazone 15 mg Tabs	10x10	21,000					

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
147	147	Pioglitazone 30 mg Tabs	10x10	21,000				
148	148	Pioglitazone 15 mg Tabs + Glimeperide 1mg	10x10	21,000				
149	149	Pioglitazone 15 mg Tabs + Glimeperide 2mg	10x10	21,000				
150	150	Pioglitazone 15 mg Tabs + Metformin 500mg	10x10	21,000				
<b>ANTI-MIGRAINE DRUGS</b>				-				
151	151	Dihydroergotamine 1 mg film coated Tablets	10x10	10,500				
<b>ANTI-NEOPLASTIC DRUGS</b>				-				
152	152	Bleomycin 15 mg Inj.	Vial	52,500				
153	153	Cisplatin 10 mg Inj.	Vial	52,500				
154	154	Cisplatin 50 mg Inj.	Vial	52,500				
155	155	Doxorubicin 10 mg Inj.	Vial	52,500				
156	156	Doxorubicin 50 mg Inj.	Vial	52,500				
157	157	Etoposide 100 mg Caps	10x10	10,500				
158	158	Etoposide 100 mg/5ml Inj.	Vial	52,500				
159	159	Gemcitabine 1000 mg Inj.	Vial	52,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	In words
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
160	160	Gemcitabine 200 mg Inj.	Vial	52,500				
161	161	Medroxyprogesterone Acetate 10 mg film coated Tablets	10x10	10,500				
162	162	Raloxifene 60 mg Tab	10x10	10,500				
163	163	Tamoxifen Citrate 10 mg Tab	10x10	10,500				
164	164	Tamoxifen Citrate 20 mg Tab	10x10	10,500				
<b>I.V.FLUIDS</b>				-				
165	165	Ciprofloxacin (2mg/ml) Infusion	100 ml bottles	52,500				
166	166	Dextrose 10% (10D)	500 ml bottles	52,500				
167	167	Dextrose 5% (5 D)	500 ml	52,500				
168	168	Glucose Normal Saline (DNS)	500 ml bottles	52,500				
169	169	Levofloxacin 500 mg Infusion	100 ml bottles	52,500				
170	170	Mannitol 20%	100 ml bottles	52,500				
171	171	Mannitol 20%	350 ml	52,500				
172	172	Metronidazole 5 mg / ml Infusion	100 ml	52,500				
173	173	Normal Saline (NS)	500 ml	52,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII			Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)			Total Value (5X7) in figures
						In figures		In words	
						RS.	Paise		
(1)	(2)	(3)	(4)	(5)	(6)	(7)			(8)
174	174	Plasma Volume Expander (Gelatin Base)	500 ml	52,500					
175	175	Ringer Lactate (RL)	500 ml	52,500					
176	176	Water for Injection	5ml Amp	105,000					
		<b>GASTROINTESTINAL TRACT/ ANTHELMINTICS</b>		-					
177	177	Albendazole (200 mg/ 5ml) Syrup	10 ml bottles	105,000					
178	178	Albendazole + Ivermectin (400 mg + 6mg) Tab	1 Tab	52,500					
179	179	Albendazole 400mg Tabs	10x10	52,500					
180	180	Bisacodyl 5mg Tablets	10x10	21,000					
181	181	Cyproheptadine HCl + Tricholine Citrate (2 mg + 275 mg) Syrup	200 ml bottles	10,500					
182	182	Dicyclomine + Mefenamic Acid (20 mg + 250 mg) Tabs	10x10	21,000					
183	183	Dicyclomine 10 mg Tabs	10x10	52,500					
184	184	Dicyclomine HCl. + Paracetamol (20 mg + 500 mg) Tabs	10x10	52,500					
185	185	Diethylcarbamazine citrate 100 mg film coated Tablets	10x10	10,500					
186	186	Domperidone 10 mg Tabs	10x10	21,000					
187	187	Domperidone 5 mg. / 5 ml Syrup	30 ml bottles	52,500					

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
188	188	Dried Al(OH) <sub>3</sub> + Mg(OH) <sub>2</sub> + Simethicone (250 + 250 + 50) mg Tabs	10x10	52,500				
189	189	Enzyme Syrup	200 ml bottles	157,500				
190	190	Enzyme film coated Tablets	10x10	157,500				
191	191	Famotidine 20 mg Tabs	10x10	10,500				
192	192	Famotidine 40 mg Tabs	10x10	52,500				
193	193	Furazolidone 100 mg Tabs	10x10	10,500				
194	194	Hyoscine Butyl Bromide 10 mg film coated Tablets	10x10	10,500				
195	195	Ispagula Husk Powder	200 g Pack	52,500				
196	196	Lactobacillus 60 million spores Tabs	10x10	10,500				
197	197	Lactulose 10 g/15 ml Syrup	100 ml bottles	31,500				
198	198	Aluminium Hydroxide + Magnesium Hydroxide (250+250mg / 5ml) Susp	170 ml	105,000				
199	199	Metoclopramide 10 mg Tabs	10x10	10,500				
200	200	Metoclopramide Inj.	2 ml	52,500				
201	201	Metronidazole 200 mg film coated Tablets	10x10	10,500				
202	202	Metronidazole 400 mg film coated Tablets	10x10	21,000				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	In words
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
203	203	Misoprostol 200 mcg film coated Tablets	4x10	10,500				
204	204	Norfloxacin + Metronidazole (100 mg+100 mg/5 ml) Syrup	30 ml bottles	21,000				
205	205	Ofloxacin+ Metronidazole (50 mg + 100mg/5 ml) Syrup	30 ml bottles	10,500				
206	206	Omeprazole + Domperidone (20 mg + 10 mg) Caps	10x10	21,000				
207	207	Omeprazole 20 mg film coated Tablets	10x10	105,000				
208	208	Ondansetron 2 mg/ml Inj.	2 ml	21,000				
209	209	Ondansetron 4 mg Tabs	10x10	21,000				
210	210	Ornidazole 500 mg film coated Tablets	10x10	21,000				
211	211	Pantoprazole 20 mg film coated Tablets	10x10	21,000				
212	212	Pantoprazole 40 mg film coated Tablets	10x10	157,500				
213	213	Pantoprazole 40 mg/ 10ml Inj.	Vial	52,500				
214	214	Rabeprazole + Domperidone SR (20 mg + 30 mg) film coated Tablets	10x10	52,500				
215	215	Rabeprazole 20 mg film coated Tablets	10x10	21,000				
216	216	Ranitidine (50 mg/ 2ml) Inj.	2ml	21,000				
217	217	Ranitidine HCl. 150 mg film coated Tablets	10x10	210,000				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
218	218	Ranitidine HCl. 300 mg film coated Tablets	10x10	52,500				
<b>VITAMINS</b>				-				
219	219	Calcium + Vitamin D <sub>3</sub> 250iu film coated Tablets	10x10	21,000				
220	220	Calcium + Vitamin D <sub>3</sub> 500iu film coated Tablets	10x10	157,500				
221	221	Calcium Citrate + Vitamin D <sub>3</sub> (100 mg + 125 iu) Syrup	150 ml bottles	52,500				
222	222	Calcium with Minerals Suspension	150ml	21,000				
223	223	Doxylamine Succinate + Pyridoxine + Folic Acid (10 mg + 10 mg + 2.5 mg) film	10x10	21,000				
224	224	Folic Acid 5mg Tabs	10x10	21,000				
225	225	Iron + Folic Acid Syrup	200 ml bottles	31,500				
226	226	Iron, Folic Acid & Zinc (Carbonil Iron) Caps	15 x10	52,500				
227	227	Polyvitamin (Prophylactic) NFI film coated Tablets	10x10	105,000				
228	228	Tonic Iron, Folic Acid & Zinc (Carbonil Iron) Syrup	200 ml bottles	52,500				
229	229	Vitamin + Iron Tonic Syrup	100 ml bottles	21,000				
230	230	Vitamin B Complex with Vitamin C & Zinc (Cebexin -Z) Caps	10x10	105,000				
231	231	Vitamin B-Complex (Prophylactic) film coated Tablets	10x10	52,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
232	232	Vitamin B-Complex NFI Syrup	200 ml bottles	21,000				
233	233	Vitamin-C Chewable 500mg Tablet	10x10	52,500				
<b>RESPIRATORY SYSTEM &amp; ANTI-ALLERGICS</b>				-				
234	234	Budesonide 0.25 mg/ml Respule	2 ml	31,500				
235	235	Budesonide 0.5 mg/ml Respule	2 ml	31,500				
236	236	Budesonide 100 mcg/dose	30 Rotacaps	21,000				
237	237	Budesonide 200 mcg	30 Rotacaps	21,000				
238	238	Budesonide 200 mcg/dose Inhaler	200 md	21,000				
239	239	Cetirizine (5 mg/ 5 ml) Syrup	60 ml bottles	52,500				
240	240	Cetirizine 10mg film coated Tablets	10x10	105,000				
241	241	Cough Syrup (Dextromethorphan Based) Syrup	100 ml bottles	52,500				
242	242	Cough Syrup CPM 3 mg. + A.Chl.110 mg. + Sod. Cit.46 mg. + Menthol IP 0.9 mg	110ml bottles	105,000				
243	243	Cough Syrup Diphen.14 mg. + A.Chl.135 mg. + Sod.Cit.57 mg. + Menthol IP 0.9	110ml bottles	105,000				
244	244	Etophyllin + Theophylline (84.7 mg + 25.3 mg) Ini.	2 ml	31,500				
245	245	Etophyllin +Theophylline (77 mg + 23 mg) Tabs	10x10	10,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII			Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)			Total Value (5X7) in figures
						In figures		In words	
						RS.	Paise		
(1)	(2)	(3)	(4)	(5)	(6)	(7)			(8)
246	246	Fexofenadine 120 mg film coated Tablets	10x10	10,500					
247	247	Fexofenadine 180 mg film coated Tablets	10x10	10,500					
248	248	Levocetirizine 5 mg film coated Tablets	10x10	105,000					
249	249	Levocetirizine HCl + Pseudoephedrine + Paracetamol (5 mg + 20 mg + 500mg)	10x10	31,500					
250	250	Montelukast Sodium 5 mg Tab	10x10	31,500					
251	251	Montelukast Sodium 10 mg Tab	10x10	52,500					
252	252	Montelukast Sodium + Levocetirizine (10 mg + 5mg) film coated Tablets	10x10	52,500					
253	253	Pheniramine Maleate 25 mg Tabs	10x10	10,500					
254	254	Promethazine (5 mg/ 5ml) Syrup	100ml bottles	52,500					
255	255	Salbutamol 100 mcg/puff Inhaler	200 md	31,500					
256	256	Salbutamol 2 mg Tabs	10x10	10,500					
257	257	Salbutamol 2.5 mg Respule	2.5 ml	31,500					
258	258	Salbutamol 200 mcg	30 Rotacaps	21,000					
259	259	Salbutamol 2mg /5ml Syrup	100 ml bottles	21,000					
260	260	Salbutamol 4 mg Tabs	10x10	21,000					

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
		<b>CARDIOVASCULAR DRUGS/ DIURETICS/HYPOLIPIDAEMIC</b>		-				
261	261	Adenosine 6 mg/ 2ml Amp.	2 ml	21,000				
262	262	Amiodarone 100 mg Tabs	10x10	10,500				
263	263	Amlodipine + Atenolol (5 mg + 50 mg) film coated Tablets	10x10	105,000				
264	264	Amlodipine 5mg film coated Tablets	10x10	52,500				
265	265	Atenolol 50 mg Tabs	14x10	105,000				
266	266	Atorvastatin 10mg film coated Tablets	10x10	105,000				
267	267	Atorvastatin 20 mg film coated Tablets+C297	10x10	52,500				
268	268	Clonidine 0.1 mg Tabs	10x10	10,500				
269	269	Clopidogrel 75mg Tabs	10x10	105,000				
270	270	Clopidogrel 75mg Tabs + Aspirin 75 mg	10x10	105,000				
271	271	Diltiazem 30 mg Tabs	10x10	52,500				
272	272	Diltiazem 60 mg Tabs	10x10	21,000				
273	273	Dobutamine 250 mg/ 20ml Inj.	Vial	10,500				
274	274	Dopamine HCl 200 mg/5ml Inj.	5 ml	21,000				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII			Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPT (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)			Total Value (5X7) in figures
						In figures		In words	
						RS.	Paise		
(1)	(2)	(3)	(4)	(5)	(6)	(7)			(8)
275	275	Enalapril 5mg Tabs	10x10	21,000					
276	276	Enoxaparin 40 mg/0.4 ml Inj.	0.4 ml	21,000					
277	277	Enoxaparin 60 mg/0.6 ml Inj.	0.6 ml	21,000					
278	278	Frusemide (10 mg/ ml)	2ml	21,000					
279	279	Frusemide 40 mg Tabs	10x10	105,000					
280	280	Heparin Sodium 1000iu/ ml Inj.	5 ml	52,500					
281	281	Heparin Sodium 5000iu/ ml Inj.	5 ml	105,000					
282	282	Hydrochlorothiazide 12.5 mg Tabs	10x10	52,500					
283	283	Isosorbide Dinitrate 10 mg Tabs	10x10	52,500					
284	284	Isosorbide Mononitrate 10 mg Tabs	10x10	52,500					
285	285	Lisinopril + Amlodipine (5 mg + 5mg) Tabs	10x10	52,500					
286	286	Lisinopril 5mg Tabs	10x10	52,500					
287	287	Losartan + H.Ch. Thaizide (50 mg + 12.5mg) film coated Tablets	10x10	52,500					
288	288	Losartan 25mg film coated Tablets	10x10	52,500					
289	289	Losartan Potassium 50 mg film coated Tablets	10x10	105,000					

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII			Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)			Total Value (5X7) in figures
						In figures		In words	
						RS.	Paise		
(1)	(2)	(3)	(4)	(5)	(6)	(7)			(8)
290	290	Metoprolol 25 mg Tabs	10x10	10,500					
291	291	Metoprolol 50 mg Tabs	10x10	10,500					
292	292	Nifedipine 10 mg Caps	10x10	10,500					
293	293	Ramipril 2.5 mg Tabs	10x10	10,500					
294	294	Ramipril 5 mg Tabs	10x10	52,500					
295	295	Simvastatin 10 mg Tabs	10x10	10,500					
296	296	Simvastatin 20 mg Tabs	10x10	21,000					
297	297	Tamsulosin Hydrochloride 0.4 mg Caps	10x10	21,000					
298	298	Telmisartan + Hydrochlorthiazide (40 mg + 12.5 mg ) Tabs	10x10	31,500					
299	299	Telmisartan 20 mg Tabs	10x10	21,000					
300	300	Telmisartan 40 mg Tabs	10x10	21,000					
301	301	Tranexamic Acid 500 mg Tabs	10x10	10,500					
302	302	Tranexamic Acid 500 mg/5ml Inj.	5 ml Amp.	10,500					
		ANTIMALARIAL DRUGS		-					
303	303	Artesunate 50mg Tabs	10x10	10,500					

Place:

Date:

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
304	304	Arteether 150mg inj	2ml Vial	10,500				
305	305	Chloroquine Phosphate 250 mg film coated Tablets	10x10	21,000				
306	306	Primaquine 15 mg film coated Tablets	10x10	10,500				
307	307	Primaquine 2.5 mg film coated Tablets	10x10	10,500				
308	308	Primaquine 5 mg film coated Tablets	10x10	10,500				
309	309	Sulphadoxine + Pyrimethamine 250 mg + 12.5 mg/5ml Syrup	10 ml bottles	21,000				
310	310	Sulphadoxine + Pyrimethamine 500 mg + 25 mg Tabs	(2X5X10)	10,500				
<b>ELECTROLYTES</b>				-				
311	311	Disodium hydrogen Citrate (Alkalyser) 1.4 mg/5ml Syrup	100 ml bottles	105,000				
312	312	Oral Rehydration Salts Citrate IP 21 GM (WHO Formula) Sachet	1S	210,000				
<b>CNS DRUGS/ANTI-EPILEPTIC DRUGS</b>				-				
313	313	Alprazolam 0.25 mg film coated Tablets	10x10	21,000				
314	314	Alprazolam 0.5 mg film coated Tablets	10x10	52,500				
315	315	Betahistine 16 mg Tabs	10x10	10,500				
316	316	Betahistine 8 mg Tabs	10x10	10,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPT (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
317	317	Carbamazepine 100mg Tabs	10x10	10,500				
318	318	Carbamazepine 200mg Tabs	10x10	21,000				
319	319	Clonazepam 0.5 mg Tabs	10x10	10,500				
320	320	Diazepam 5 mg Tabs	10x10	21,000				
321	321	Escitalopram 10 mg Tabs	10x10	10,500				
322	322	Escitalopram 20 mg Tabs	10x10	10,500				
323	323	Flunarzine 10mg Tabs	10x10	31,500				
324	324	Flunarzine 5mg Tabs	10x10	21,000				
325	325	Fluoxetine hydrochloride 20 mg Caps	10x10	10,500				
326	326	Methyl Ergometrine 0.125mg Tabs	10x10	10,500				
327	327	Phenytoin Sodium 100 mg Tabs	10x10	21,000				
328	328	Prochlorperazine 5 mg Tabs	10x10	21,000				
<b>CORTICO – STEROIDS/DRUG USED IN HYPOTHYRIODISM</b>				-				
329	329	Prednisolone 5 mg Tabs	10x10	21,000				
330	330	Prednisolone 10 mg Tabs	10x10	31,500				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

## BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPT (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
331	331	Thyroxine Sodium 50 mcg Tabs	10x10	21,000				
332	332	Thyroxine Sodium 100 mcg Tabs	10x10	21,000				
333	333	Dexamethasone 0.5 mg Tabs	10x10	21,000				
334	334	Dexamethasone 40 mg Inj.	2 ml	105,000				
<b>DIETARY SUPPLEMENT</b>				-				
335	335	Protein Powder	200 g Jar	105,000				
<b>DRUGS USED IN GOUT</b>				-				
336	336	Allopurinol 100 mg Tabs	10x10	10,500				
<b>HORMONES AND RELATED DRUGS</b>				-				
337	337	Clomiphene citrate 50 mg Tabs	10x10	10,500				
<b>OPHTHALMIC PREPARATION</b>				-				
338	338	Atropine Sulphate (0.6mg/ ml) Inj.	1ml	52,500				
339	339	Betaxolol Hydrochloride 0.5 % w/w Eye Drop	5 ml	52,500				
340	340	Acyclovir 3% w/w Eye Onit.	5 g	105,000				
341	341	Carboxymethyl Cellulose 0.5 % w/v Eye Drop	10 ml	31,500				

Place:

Date:

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

## BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII		Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)		Total Value (5X7) in figures
						In figures		
						RS.	Paise	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
342	342	Chloramphenicol 1 % w/v Eye Drop	5 ml	52,500				
343	343	Chloramphenicol 1 % w/v Eye Applicaps	100 Applicaps	105,000				
344	344	Ciprofloxacin 0.3% w/v Eye Drop	5 ml	315,000				
345	345	Gentamycin 0.3% w/v Eye Drop	5 ml	105,000				
346	346	Ketorolac Tromethamine 0.5 % w/v Eye Drop	5 ml	52,500				
347	347	Prednisolone Acetate 1 % w/v Eye Drop	5 ml	52,500				
348	348	Sulphacetamide Sodium 10 % w/v Eye Drop	10 ml	105,000				
349	349	Sulphacetamide Sodium 20 % w/v Eye Drop	10 ml	105,000				
350	350	Timolol Maleate 0.5 % w/v Eye Drop	5 ml	52,500				
<b>OROPHARYNGEAL</b>				-				
351	351	Xylometazoline 0.1 % w/v Nasal Drop	10 ml	105,000				
<b>SURGICAL ANESTHETICS</b>				-				
352	352	Bupivacaine Hydrochloride 0.5% w/w Inj.	4 ml X 5	21,000				
353	353	Ketamine Hydrochloride 10 mg/ml Inj.	10 ml	21,000				
354	354	Ketamine Hydrochloride 50 mg/ml Inj.	2 ml	21,000				

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

Place:

Date:

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Break up of landed price				Aneexture XVIII			Refer Clause 5(iii,vi,vii,xii)		
Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Quantity of supply in units	Manufacturing capacity earmarked for BPPI (1 Year)	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT)			Total Value (5X7) in figures
						In figures		In words	
						RS.	Paise		
(1)	(2)	(3)	(4)	(5)	(6)	(7)			(8)
355	355	Lignocaine 1% w/v Inj.	20 ml Vial	31,500					
356	356	Lignocaine 2% w/v Inj.	20 ml Vial	31,500					
357	357	Lignocaine + Adrenaline (1% + 2%)w/v Inj.	30 ml Vial	31,500					
358	358	Propofol 10 mg/ml Inj.	10ml Vial	21,000					
		<b>VACCINES</b>		-					
359	359	Tetanus Toxoid Inj.	0.5 ml Amp.	1,050,000					
		<b>OTHERS</b>		-					
360	360	Mifepristone 200 mg Tabs	1x10	10,500					
361	361	Oxytocin 5 iu / ml Inj.	1 ml Amp.	52,500					

Place:

Date:

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Designation: \_\_\_\_\_

# BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, GURGAON 122016

Annexure - XIX

Ref Clause 5

## Break up of landed price

Note: The firms should indicate breakup prices at column 4 to 7 and 9, 10, 11 seperatly and wording like "included" should not be substituted for the same

As per specifications laid down in relevant pharmacopieas

Sl. No	Drug Code	Generic Name of the Medicines	Pack Size	Basic price inclusive of incidental services	Packing and Forwarding Charges	Excise/Custom Duty	Freight and Insurance charges	Total landed price (4+5+6+7)	CST %	VAT %	Excise/Customs duty %
(1)	(2)	(3)		(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
		<b>ANALGESIC/ ANTI-INFLAMMATORY/ MUSCLOSKELETAL DISORDER</b>									
1	1	Aceclofenac + Paracetamol (100 mg + 500mg) Tablets	10x10								
2	2	Aceclofenac 100 mg Tablets	10x10								
3	3	Aceclofenac Gel	30 g tubes								
4	4	Acetaminophen + Tramadol Hydrochloride (325 mg + 37.5 mg) film coated Tablets	10x10								
5	5	Asprin 150 mg Tab	14x10								
6	6	Chlorzoxazone + Diclofenac + Paracetamol (500 mg + 50 mg + 500	10x10								
7	7	Diclofenac Gel	15 g								
8	8	Diclofenac Sodium + Serratiopeptidase (50mg + 10mg) Tab	10x10								
9	9	Diclofenac Sodium (SR) 100 mg Tab	10x10								
10	10	Diclofenac Sodium 25mg per ml Inj.	3 ml								
11	11	Diclofenac Sodium 50 mg Tab	10x10								

12	12	Etoricoxib 120mg Tab	10x10								
13	13	Etoricoxib 90mg Tab	10x10								
14	14	Ibuprofen + Paracetamol (400 mg + 325 mg) Tab	10x10								
15	15	Ibuprofen 200mg film coated Tablets	10x10								
16	16	Ibuprofen 400 mg film coated Tablets	10x10								
17	17	Indomethacin 25 mg Cap	10x10								
18	18	Methyl Salicylate Oint.(Eutheria)	20 g								
19	19	Nimesulide + Paracetamol (100 mg + 500mg) Tab	10x10								
20	20	Nimesulide 100 mg Tab	10x10								
21	21	Paracetamol + Diclofenac Sodium (500 mg + 50 mg) Tab	10x10								
22	22	Paracetamol 125 mg / 5 ml Syrup	60 ml bottles								
23	23	Paracetamol 500mg Tab	10x10								
24	24	Pentazocine 30 mg/ ml Inj.	1 ml								
25	25	Serratiopeptidase 10 mg Tab	10x10								
26	26	Tramadol 100 mg Inj.	2ml								
27	27	Tramadol 50 mg Inj.	1ml								
28	28	Tramadol 50 mg Tab	10x10								
<b>ANTIBIOTICS</b>											
29	29	Acyclovir 400 mg film coated Tablets	10x10								
30	30	Amikacin 100mg inj.	Vial								



31	31	Amikacin 250mg inj.	Vial								
32	32	Amikacin 500mg inj.	Vial								
33	33	Amoxycillin + Bromhexine (250 mg + 8 mg) Caps	10x10								
34	34	Amoxycillin + Bromhexine (500 mg + 8 mg) Caps	10x10								
35	35	Amoxycillin + Clavulanic acid (1000 mg + 200mg) Ini.	Vial								
36	36	Amoxycillin + Clavulanic acid (200 mg+28.5 mg /5ml) Dry Syrup	30 ml bottles								
37	37	Amoxycillin + Clavulanic acid (250 mg + 50 mg) Ini.	Vial								
38	38	Amoxycillin + Clavulanic acid (500 mg + 100mg) Ini.	Vial								
39	39	Amoxycillin + Clavulanic acid (500 mg + 125 mg) film coated Tablets	6x10								
40	40	Amoxycillin + Cloxacillin (250 mg + 250 mg) Caps	10x10								
41	41	Amoxycillin + Di-Cloxacillin (250 mg + 250 mg) Caps	10x10								
42	42	Amoxycillin 125 mg Kid Tabs	10x10								
43	43	Amoxycillin 125mg/ 5ml Dry Syrup	60 ml bottles								
44	44	Amoxycillin 250 mg Caps	10x10								
45	45	Amoxycillin 500 mg Caps	10x10								
46	46	Ampicillin 500mg inj.	Vial								
47	47	Azithromycin (100mg/ 5ml) Syrup	15 ml bottles								
48	48	Azithromycin 100 mg DT Tab	10x10								
49	49	Azithromycin 250 mg film coated Tablets	10x10								
50	50	Azithromycin 500 mg film coated Tablets	10x10								

51	51	Cefadroxil 250 mg film coated Tablets	10x10								
52	52	Cefadroxil 500 mg film coated Tablets	10x10								
53	53	Cefixime (50 mg/ 5ml) Dry Syrup	30 ml bottles								
54	54	Cefixime 100mg film coated Tablets	10x10								
55	55	Cefixime 200mg film coated Tablets	10x10								
56	56	Cefoperazone + Sulbactam ( 1g + 1g) Inj.	vial								
57	57	Cefoperazone + Sulbactam (500 mg + 500 mg) Inj.	vial								
58	58	Cefoperazone 1 gm Inj.	Vial								
59	59	Cefotaxime Sodium & Sulbactam Sodium (1g + 500 mg) Inj.	Vial								
60	60	Cefotaxime Sodium & Sulbactam Sodium (250 mg + 125 mg) Inj.	Vial								
61	61	Cefotaxime Sodium & Sulbactam Sodium (500 mg + 250 mg) Inj.	Vial								
62	62	Cefotaxime Sodium 1000mg Inj.	Vial								
63	63	Cefotaxime Sodium 250 mg Inj.	Vial								
64	64	Cefotaxime Sodium 500 mg Inj.	Vial								
65	65	Cefpodoxime 100 mg DT	10x10								
66	66	Cefpodoxime 200 mg film coated Tablets	10x10								
67	67	Ceftazadime 1000 mg Inj.	Vial								
68	68	Ceftazadime 250 mg Inj.	Vial								
69	69	Ceftazadime 500 mg Inj.	Vial								
70	70	Ceftriaxone + Sulbactam (1000 mg + 500 mg) Inj.	Vial								

71	71	Ceftriaxone + Tazobactam 1000 mg + 125 mg Ini.	Vial & wfi								
72	72	Ceftriaxone + Tazobactam 250 mg + 31.25 mg Ini.	Vial & wfi								
73	73	Ceftriaxone +Sulbactam (250 mg + 125 mg)	Vial								
74	74	Ceftriaxone +Sulbactam (500 mg + 250 mg)	Vial								
75	75	Ceftriaxone 1 g Inj.	Vial								
76	76	Ceftriaxone 250 mg Inj.	Vial								
77	77	Ceftriaxone 500 mg Inj.	Vial								
78	78	Cefuroxime Axetil 250 mg film coated Tablets	10x10								
79	79	Cefuroxime Axetil 500mg film coated Tablets	10x10								
80	80	Cephalexin 125 mg DT	10x10								
81	81	Cephalexin 250 mg Caps	10x10								
82	82	Cephalexin 500 mg Caps	10x10								
83	83	Ciprofloxacin + Tinidazole (250 mg + 300 mg) film coated Tablets	10x10								
84	84	Ciprofloxacin + Tinidazole (500 mg + 600 mg) film coated Tablets	10x10								
85	85	Ciprofloxacin 250 mg film coated Tablets	10x10								
86	86	Ciprofloxacin 500 mg film coated Tablets	10x10								
87	87	Clotrimazole 1% w/w Oint.	15 g tubes								
88	88	Co-trimoxazole (Sulphamethoxazole 200mg + Trimethoprim 40mg / 5ml)	50 ml bottle								
89	89	Co-trimoxazole -DS (160 mg + 800 mg) Tabs	10x10								
90	90	Co-trimoxazole- Pead. (20 mg + 100 mg) Tabs	10x10								

91	91	Co-trimoxazole –SS (80 mg + 400 mg)	10x10								
92	92	Doxycycline 100 mg Caps	10x10								
93	93	Erythromycin Stearate 250 mg film coated Tablets	10x10								
94	94	Gentamycin Sulphate 80 mg/ 2ml Inj.	2 ml								
95	95	Levofloxacin 250 mg film coated Tablets	10x10								
96	96	Levofloxacin 500 mg film coated Tablets	10x10								
97	97	Meropenem 1gm Inj.	Vial								
98	98	Norfloxacin + Tinidazole (400 mg + 600 mg) film coated Tablets	10x10								
99	99	Norfloxacin 400 mg film coated Tablets	10x10								
100	100	Ofloxacin + Ornidazole (200 mg + 500 mg) film coated Tablets	10x10								
101	101	Ofloxacin 200 mg film coated Tablets	10x10								
102	102	Ofloxacin 400 mg film coated Tablets	10x10								
103	103	Piperacillin + Tazobactam 4 g + 0.5 mg Inj.	Vial & wfi								
104	104	Roxithromycin (50 mg/ 5ml) Susp.	30 ml bottles								
105	105	Roxithromycin 150 mg film coated Tablets	10x10								
106	106	Roxithromycin 300 mg film coated Tablets	10x10								
107	107	Tinidazole 300 mg film coated Tablets	10x10								
108	108	Tinidazole 500 mg film coated Tablets	10x10								
109	109	Vancomycin 500 mg	Vial								
<b>ANTI INFECTIVES (TOPICALS)/ ANTIFUNGAL/ SKIN OINTMENT</b>											

110	110	Adapalene 0.1 % w/v Ointment	15 g tubes								
111	111	Application Benzyl Benzoate 25 % w/w Lotion	100 ml								
112	112	Beclomethasone + Clotrimazole + Gentamycin (0.025%+1.0%+0.1% w/w)	15 g tubes								
113	113	Beclomethasone + Neomycin (0.025% + 0.5% w/w) Cream	15 g tubes								
114	114	Beclomethasone Dipropionate 0.025% w/v Oint.	15 g tubes								
115	115	Calamine Lotion	100 ml bottles								
116	116	Chlorhexidine Gluconate 5% Solution	500 ml bottles								
117	117	Chlorhexidine Gluconate 0.2% Mouth Wash	150 ml bottles								
118	118	Clobetasol Propionate 0.05 % w/w Cream	15 g tubes								
119	119	Fluconazole 150 mg film coated Tablets	10x10								
120	120	Fusidic Acid 2 % w/v Cream	10 g tubes								
121	121	Glutaraldehyde 2% w/v Solution	500 ml bottles								
122	122	Ketoconazole 2 % w/w Lotion	100 ml bottles								
123	123	Lignocaine 2% w/w Ointment	30 g tubes								
124	124	Povidone Iodine 5% w/w Ointment	250 gm tubes								
125	125	Povidone Iodine 5%w/w Ointment	15 gm tubes								
126	126	Povidone Iodine 10 % Solution	500 ml bottles								
127	127	Povidone Iodine 5 % Solution	100 ml bottles								
128	128	Povidone Iodine 5 % Solution	500 ml bottles								
129	129	Povidone Iodine 7.5% Solution	500 ml bottles								

130	130	Ravlon Solution (Chlorhexidine + Cetramide ) (1.5 % w/v + 3% w/v)	100 ml bottles								
131	131	Silver Sulphadiazine 1 % w/w Cream	20 gm tubes								
132	132	Silver Sulphadiazine 1 % w/w Cream	500 gm jars								
<b>ANTIDIABETIC DRUGS</b>											
133	133	Glibenclamide 2.5 mg Tabs (Scored Oval)	10x10								
134	134	Glibenclamide 5 mg Tabs (Scored Oval)	10x10								
135	135	Gliclazide 40 mg Tabs	10x10								
136	136	Gliclazide 80 mg Tabs	10x10								
137	137	Glimeperide 1mg Tab	10x10								
138	138	Glimeperide 2mg Tabs	10x10								
139	139	Glimeperide 1mg + Metformin 500mg + Pioglitazone 15mg	10x10								
140	140	Glimeperide 2mg + Metformin 500mg + Pioglitazone 15mg	10x10								
141	141	Glipizide 5 mg Tabs	10x10								
142	142	Insulin Injection (Human) (40iu/ml)	10 ml Vial								
143	143	Insulin Injection {Insulin Human (Soluble 30% & Isophane 70%) 40iu/ml}	10 ml Vial								
144	144	Metformin Hydrochloride 1000 mg SR Tabs	10x10								
145	145	Metformin Hydrochloride 500mg Tabs	10x10								
146	146	Pioglitazone 15 mg Tabs	10x10								
147	147	Pioglitazone 30 mg Tabs	10x10								
148	148	Pioglitazone 15 mg Tabs + Glimeperide 1mg	10x10								

149	149	Pioglitazone 15 mg Tabs + Glimeperide 2mg	10x10								
150	150	Pioglitazone 15 mg Tabs + Metformin 500mg	10x10								
<b>ANTI-MIGRAINE DRUGS</b>											
151	151	Dihydroergotamine 1 mg film coated Tablets	10x10								
<b>ANTI-NEOPLASTIC DRUGS</b>											
152	152	Bleomycin 15 mg Inj.	Vial								
153	153	Cisplatin 10 mg Inj.	Vial								
154	154	Cisplatin 50 mg Inj.	Vial								
155	155	Doxorubicin 10 mg Inj.	Vial								
156	156	Doxorubicin 50 mg Inj.	Vial								
157	157	Etoposide 100 mg Caps	10x10								
158	158	Etoposide 100 mg/5ml Inj.	Vial								
159	159	Gemcitabine 1000 mg Inj.	Vial								
160	160	Gemcitabine 200 mg Inj.	Vial								
161	161	Medroxyprogesterone Acetate 10 mg film coated Tablets	10x10								
162	162	Raloxifene 60 mg Tab	10x10								
163	163	Tamoxifen Citrate 10 mg Tab	10x10								
164	164	Tamoxifen Citrate 20 mg Tab	10x10								
<b>I.V.FLUIDS</b>											
165	165	Ciprofloxacin (2mg/ml) Infusion	100 ml bottles								

166	166	Dextrose 10% (10D)	500 ml bottles								
167	167	Dextrose 5% (5 D)	500 ml								
168	168	Glucose Normal Saline (DNS)	500 ml bottles								
169	169	Levofloxacin 500 mg Infusion	100 ml bottles								
170	170	Mannitol 20%	100 ml bottles								
171	171	Mannitol 20%	350 ml								
172	172	Metronidazole 5 mg / ml Infusion	100 ml								
173	173	Normal Saline (NS)	500 ml								
174	174	Plasma Volume Expander (Gelatin Base)	500 ml								
175	175	Ringer Lactate (RL)	500 ml								
176	176	Water for Injection	5ml Amp								
<b>GASTROINTESTINAL TRACT/ ANTHELMINTICS</b>											
177	177	Albendazole (200 mg/ 5ml) Syrup	10 ml bottles								
178	178	Albendazole + Ivermectin (400 mg + 6mg) Tab	1 Tab								
179	179	Albendazole 400mg Tabs	10x10								
180	180	Bisacodyl 5mg Tablets	10x10								
181	181	Cyproheptadine HCl + Tricholine Citrate (2 mg + 275 mg) Syrup	200 ml bottles								
182	182	Dicyclomine + Mefenamic Acid (20 mg + 250 mg) Tabs	10x10								
183	183	Dicyclomine 10 mg Tabs	10x10								
184	184	Dicyclomine HCl. + Paracetamol (20 mg + 500 mg) Tabs	10x10								



185	185	Diethylcarbamazine citrate 100 mg film coated Tablets	10x10								
186	186	Domperidone 10 mg Tabs	10x10								
187	187	Domperidone 5 mg. / 5 ml Syrup	30 ml bottles								
188	188	Dried Al(OH) <sub>3</sub> + Mg(OH) <sub>2</sub> + Simethicone (250 + 250 + 50) mg Tabs	10x10								
189	189	Enzyme Syrup	200 ml bottles								
190	190	Enzyme film coated Tablets	10x10								
191	191	Famotidine 20 mg Tabs	10x10								
192	192	Famotidine 40 mg Tabs	10x10								
193	193	Furazolidone 100 mg Tabs	10x10								
194	194	Hyoscine Butyl Bromide 10 mg film coated Tablets	10x10								
195	195	Ispagula Husk Powder	200 g Pack								
196	196	Lactobacillus 60 million spores Tabs	10x10								
197	197	Lactulose 10 g/15 ml Syrup	100 ml bottles								
198	198	Aluminium Hydroxide + Magnesium Hydroxide (250+250mg / 5ml) Susp	170 ml								
199	199	Metoclopramide 10 mg Tabs	10x10								
200	200	Metoclopramide Inj.	2 ml								
201	201	Metronidazole 200 mg film coated Tablets	10x10								
202	202	Metronidazole 400 mg film coated Tablets	10x10								
203	203	Misoprostol 200 mcg film coated Tablets	4x10								
204	204	Norfloxacin + Metronidazole (100 mg+100 mg/5 ml) Syrup	30 ml bottles								

205	205	Ofloxacin+ Metronidazole (50 mg + 100mg/5 ml) Syrup	30 ml bottles								
206	206	Omeprazole + Domperidone (20 mg + 10 mg) Caps	10x10								
207	207	Omeprazole 20 mg film coated Tablets	10x10								
208	208	Ondansetron 2 mg/ml Inj.	2 ml								
209	209	Ondansetron 4 mg Tabs	10x10								
210	210	Ornidazole 500 mg film coated Tablets	10x10								
211	211	Pantoprazole 20 mg film coated Tablets	10x10								
212	212	Pantoprazole 40 mg film coated Tablets	10x10								
213	213	Pantoprazole 40 mg/ 10ml Inj.	Vial								
214	214	Rabeprazole + Domperidone SR (20 mg + 30 mg) film coated Tablets	10x10								
215	215	Rabeprazole 20 mg film coated Tablets	10x10								
216	216	Ranitidine (50 mg/ 2ml) Inj.	2ml								
217	217	Ranitidine HCl. 150 mg film coated Tablets	10x10								
218	218	Ranitidine HCl. 300 mg film coated Tablets	10x10								
<b>VITAMINS</b>											
219	219	Calcium + Vitamin D <sub>3</sub> 250iu film coated Tablets	10x10								
220	220	Calcium + Vitamin D <sub>3</sub> 500iu film coated Tablets	10x10								
221	221	Calcium Citrate + Vitamin D <sub>3</sub> (100 mg + 125 iu) Syrup	150 ml bottles								
222	222	Calcium with Minerals Suspension	150ml								
223	223	Doxylamine Succinate + Pyridoxine + Folic Acid (10 mg + 10 mg + 2.5 mg)	10x10								

224	224	Folic Acid 5mg Tabs	10x10								
225	225	Iron + Folic Acid Syrup	200 ml bottles								
226	226	Iron, Folic Acid & Zinc (Carbonil Iron) Caps	15 x10								
227	227	Polyvitamin (Prophylactic) NFI film coated Tablets	10x10								
228	228	Tonic Iron, Folic Acid & Zinc (Carbonil Iron) Syrup	200 ml bottles								
229	229	Vitamin + Iron Tonic Syrup	100 ml bottles								
230	230	Vitamin B Complex with Vitamin C & Zinc (Cebexin -Z) Caps	10x10								
231	231	Vitamin B-Complex (Prophylactic) film coated Tablets	10x10								
232	232	Vitamin B-Complex NFI Syrup	200 ml bottles								
233	233	Vitamin-C Chewable 500mg Tablet	10x10								
<b>RESPIRATORY SYSTEM &amp; ANTI-ALLERGICS</b>											
234	234	Budesonide 0.25 mg/ml Respule	2 ml								
235	235	Budesonide 0.5 mg/ml Respule	2 ml								
236	236	Budesonide 100 mcg/dose	30 Rotacap								
237	237	Budesonide 200 mcg	30 Rotacap								
238	238	Budesonide 200 mcg/dose Inhaler	200 md								
239	239	Cetirizine (5 mg/ 5 ml) Syrup	60 ml bottles								
240	240	Cetirizine 10mg film coated Tablets	10x10								
241	241	Cough Syrup (Dextromethorphan Based) Syrup	100 ml bottles								
242	242	Cough Syrup CPM 3 mg. + A.Chl.110 mg. +Sod. Cit.46 mg. + Menthol IP 0.9	110ml bottles								

243	243	Cough Syrup Diphen.14 mg. + A.Chl.135 mg. + Sod.Cit.57 mg. + Menthol IP 0.9	110ml bottles								
244	244	Etophyllin + Theophylline (84.7 mg + 25.3 mg) Ini.	2 ml								
245	245	Etophyllin +Theophylline (77 mg + 23 mg) Tabs	10x10								
246	246	Fexofenadine 120 mg film coated Tablets	10x10								
247	247	Fexofenadine 180 mg film coated Tablets	10x10								
248	248	Levocetirizine 5 mg film coated Tablets	10x10								
249	249	Levocetirizine HCl + Pseudoephedrine + Paracetamol (5 mg + 20 mg + 500mg)	10x10								
250	250	Montelukast Sodium 5 mg Tab	10x10								
251	251	Montelukast Sodium 10 mg Tab	10x10								
252	252	Montelukast Sodium + Levocetirizine (10 mg + 5mg) film coated Tablets	10x10								
253	253	Pheniramine Maleate 25 mg Tabs	10x10								
254	254	Promethazine (5 mg/ 5ml) Syrup	100ml bottles								
255	255	Salbutamol 100 mcg/puff Inhaler	200 md								
256	256	Salbutamol 2 mg Tabs	10x10								
257	257	Salbutamol 2.5 mg Respule	2.5 ml								
258	258	Salbutamol 200 mcg	30 Rotacap								
259	259	Salbutamol 2mg /5ml Syrup	100 ml bottles								
260	260	Salbutamol 4 mg Tabs	10x10								
<b>CARDIOVASCULAR DRUGS/ DIURETICS/HYPOLIPIDAEMIC</b>											
261	261	Adenosine 6 mg/ 2ml Amp.	2 ml								

262	262	Amiodarone 100 mg Tabs	10x10								
263	263	Amlodipine + Atenolol (5 mg + 50 mg) film coated Tablets	10x10								
264	264	Amlodipine 5mg film coated Tablets	10x10								
265	265	Atenolol 50 mg Tabs	14x10								
266	266	Atorvastatin 10mg film coated Tablets	10x10								
267	267	Atorvastatin 20 mg film coated Tablets+C297	10x10								
268	268	Clonidine 0.1 mg Tabs	10x10								
269	269	Clopidogrel 75mg Tabs	10x10								
270	270	Clopidogrel 75mg Tabs + Aspirin 75 mg	10x10								
271	271	Diltiazem 30 mg Tabs	10x10								
272	272	Diltiazem 60 mg Tabs	10x10								
273	273	Dobutamine 250 mg/ 20ml Inj.	Vial								
274	274	Dopamine HCl 200 mg/5ml Inj.	5 ml								
275	275	Enalapril 5mg Tabs	10x10								
276	276	Enoxaparin 40 mg/0.4 ml Inj.	0.4 ml								
277	277	Enoxaparin 60 mg/0.6 ml Inj.	0.6 ml								
278	278	Frusemide (10 mg/ ml)	2ml								
279	279	Frusemide 40 mg Tabs	10x10								
280	280	Heparin Sodium 1000iu/ ml Inj.	5 ml								
281	281	Heparin Sodium 5000iu/ ml Inj.	5 ml								

282	282	Hydrochlorothiazide 12.5 mg Tabs	10x10								
283	283	Isosorbide Dinitrate 10 mg Tabs	10x10								
284	284	Isosorbide Mononitrate 10 mg Tabs	10x10								
285	285	Lisinopril + Amlodipine (5 mg + 5mg) Tabs	10x10								
286	286	Lisinopril 5mg Tabs	10x10								
287	287	Losartan + H.Ch. Thaizide (50 mg + 12.5mg) film coated Tablets	10x10								
288	288	Losartan 25mg film coated Tablets	10x10								
289	289	Losartan Potassium 50 mg film coated Tablets	10x10								
290	290	Metoprolol 25 mg Tabs	10x10								
291	291	Metoprolol 50 mg Tabs	10x10								
292	292	Nifedipine 10 mg Caps	10x10								
293	293	Ramipril 2.5 mg Tabs	10x10								
294	294	Ramipril 5 mg Tabs	10x10								
295	295	Simvastatin 10 mg Tabs	10x10								
296	296	Simvastatin 20 mg Tabs	10x10								
297	297	Tamsulosin Hydrochloride 0.4 mg Caps	10x10								
298	298	Telmisartan + Hydrochlorthiazide (40 mg + 12.5 mg ) Tabs	10x10								
299	299	Telmisartan 20 mg Tabs	10x10								
300	300	Telmisartan 40 mg Tabs	10x10								
301	301	Tranexamic Acid 500 mg Tabs	10x10								

302	302	Tranexamic Acid 500 mg/5ml Inj.	5 ml Amp.								
<b>ANTIMALARIAL DRUGS</b>											
303	303	Artesunate 50mg Tabs	10x10								
304	304	Arteether 150mg inj	2ml Vial								
305	305	Chloroquine Phosphate 250 mg film coated Tablets	10x10								
306	306	Primaquine 15 mg film coated Tablets	10x10								
307	307	Primaquine 2.5 mg film coated Tablets	10x10								
308	308	Primaquine 5 mg film coated Tablets	10x10								
309	309	Sulphadoxine + Pyrimethamine 250 mg + 12.5 mg/5ml Syrup	10 ml bottles								
310	310	Sulphadoxine + Pyrimethamine 500 mg + 25 mg Tabs	(2X5X10 )								
<b>ELECTROLYTES</b>											
311	311	Disodium hydrogen Citrate (Alkalyser) 1.4 mg/5ml Syrup	100 ml bottles								
312	312	Oral Rehydration Salts Citrate IP 21 GM (WHO Formula) Sachet	1S								
<b>CNS DRUGS/ANTI-EPILEPTIC DRUGS</b>											
313	313	Alprazolam 0.25 mg film coated Tablets	10x10								
314	314	Alprazolam 0.5 mg film coated Tablets	10x10								
315	315	Betahistine 16 mg Tabs	10x10								
316	316	Betahistine 8 mg Tabs	10x10								
317	317	Carbamazepine 100mg Tabs	10x10								
318	318	Carbamazepine 200mg Tabs	10x10								

319	319	Clonazepam 0.5 mg Tabs	10x10								
320	320	Diazepam 5 mg Tabs	10x10								
321	321	Escitalopram 10 mg Tabs	10x10								
322	322	Escitalopram 20 mg Tabs	10x10								
323	323	Flunarzine 10mg Tabs	10x10								
324	324	Flunarzine 5mg Tabs	10x10								
325	325	Fluoxetine hydrochloride 20 mg Caps	10x10								
326	326	Methyl Ergometrine 0.125mg Tabs	10x10								
327	327	Phenytoin Sodium 100 mg Tabs	10x10								
328	328	Prochlorperazine 5 mg Tabs	10x10								
<b>CORTICO – STEROIDS/DRUG USED IN HYPOTHYROIDISM</b>											
329	329	Prednisolone 5 mg Tabs	10x10								
330	330	Prednisolone 10 mg Tabs	10x10								
331	331	Thyroxine Sodium 50 mcg Tabs	10x10								
332	332	Thyroxine Sodium 100 mcg Tabs	10x10								
333	333	Dexamethasone 0.5 mg Tabs	10x10								
334	334	Dexamethasone 40 mg Inj.	2 ml								
<b>DIETARY SUPPLEMENT</b>											
335	335	Protein Powder	200 g Jar								
<b>DRUGS USED IN GOUT</b>											



336	336	Allopurinol 100 mg Tabs	10x10								
<b>HORMONES AND RELATED DRUGS</b>											
337	337	Clomiphene citrate 50 mg Tabs	10x10								
<b>OPHTHALMIC PREPARATION</b>											
338	338	Atropine Sulphate (0.6mg/ ml) Inj.	1ml								
339	339	Betaxolol Hydrochloride 0.5 % w/w Eye Drop	5 ml								
340	340	Acyclovir 3% w/w Eye Onit.	5 g								
341	341	Carboxymethyl Cellulose 0.5 % w/v Eye Drop	10 ml								
342	342	Chloramphenicol 1 % w/v Eye Drop	5 ml								
343	343	Chloramphenicol 1 % w/v Eye Applicaps	100 Applicap								
344	344	Ciprofloxacin 0.3% w/v Eye Drop	5 ml								
345	345	Gentamycin 0.3% w/v Eye Drop	5 ml								
346	346	Ketorolac Tromethamine 0.5 % w/v Eye Drop	5 ml								
347	347	Prednisolone Acetate 1 % w/v Eye Drop	5 ml								
348	348	Sulphacetamide Sodium 10 % w/v Eye Drop	10 ml								
349	349	Sulphacetamide Sodium 20 % w/v Eye Drop	10 ml								
350	350	Timolol Maleate 0.5 % w/v Eye Drop	5 ml								
<b>OROPHARYNGEAL</b>											
351	351	Xylometazoline 0.1 % w/v Nasal Drop	10 ml								
<b>SURGICAL ANESTHETICS</b>											

352	352	Bupivacaine Hydrochloride 0.5% w/w Inj.	4 ml X 5								
353	353	Ketamine Hydrochloride 10 mg/ml Inj.	10 ml								
354	354	Ketamine Hydrochloride 50 mg/ml Inj.	2 ml								
355	355	Lignocaine 1% w/v Inj.	20 ml Vial								
356	356	Lignocaine 2% w/v Inj.	20 ml Vial								
357	357	Lignocaine + Adrenaline (1% + 2%)w/v Inj.	30 ml Vial								
358	358	Propofol 10 mg/ml Inj.	10ml Vial								
<b>VACCINES</b>											
359	359	Tetanus Toxoid Inj.	0.5 ml Amp.								
<b>OTHERS</b>											
360	360	Mifepristone 200 mg Tabs	1x10								
361	361	Oxytocin 5 iu / ml Inj.	1 ml Amp.								